title,content,hyperlink,type
ゾルトファイ配合注(インスリンデグルデク/リラグルチド)の作用機序[糖尿病] - 新薬情報オンライン,"2019年5月28日、厚労省の薬食審・医薬品第一部会にて「2型糖尿病」を対象疾患とするゾルトファイ配合注フレックスタッチ(一般名：インスリンデグルデク/リラグルチド)の承認可否について審議される予定です.現時点では未承認のためご注意ください.基本情報製品名ゾルトファイ配合注フレックスタッチ一般名インスリン デグルデク(遺伝子組換え) リラグルチド(遺伝子組換え)製造販売ノボ ノルディスク ファーマ(株)効能・効果2型糖尿病(仮)用法・用量未定収載時の薬価薬価未収載 ゾルトファイはインスリン製剤とGLP-1受容体作動薬(GLP-1アナログ製剤)を配合した初の薬剤ですね!トレシーバ注 フレックスタッチ(インスリン デグルデク)：持続型インスリン製剤ビクトーザ皮下注(リラグルチド)：GLP-1受容体作動薬 新薬情報2型糖尿病ではしばしばインスリン製剤とGLP-1受容体作動薬が併用されることがありますので、合剤にすることで簡便性が向上しそうです. 今回は体内の血糖調節システムと糖尿病、そしてゾルトファイの作用機序等について解説します. 生体内の血糖調節システム通常、生体内では以下のいくつかのホルモン等によって血糖が一定に保たれています. ＜血糖を上昇させる生体内物質＞グルカゴンアドレナリンノルアドレナリンコルチゾール成長ホルモン＜血糖を下降させる生体内物質＞ このように、血糖を上昇させる物質は数種類存在していますが、血糖を下降する物質はインスリンしかありません. インスリンの作用とGLP-1インスリンは膵臓から分泌されるホルモンです.分泌されたインスリンは、細胞に作用することで血中のブドウ糖を細胞内に取り込む働きがあります. 新薬情報この働きによって、血中のブドウ糖を下げる(血糖値の降下)作用を発揮します. また、インスリンの分泌を促進させる物質の一つに「GLP-1」と呼ばれるホルモンがあります.GLP-1は食事が小腸を通過することで分泌されるホルモンで、以下のような働きを有します.インスリン分泌促進(血糖依存的)グルカゴン分泌抑制(血糖依存的)胃排泄遅延食欲抑制血糖値が低い時にはインスリンの分泌を促進しないため、過剰に分泌されても低血糖になる恐れがありません.しかし、GLP-1は「DPP-4」と呼ばれるタンパク質によって半減期1～2分ほどの早さで速やかに分解され、効果はすぐ失われます. 糖尿病とは平成26年の厚労省調査によると、糖尿病の総患者数は316万6,000人であり、前回の調査よりも46万人以上増加しているようです.糖尿病はその名の通り、血中ブドウ糖濃度が高い状態が慢性的に継続している病態です. 健康診断等で空腹時血糖値が126mg/dL以上HbA1cが6.5%以上の場合に疑われ、数回の検査を経て確定診断されます. 糖尿病には、 遺伝的要因が関与する「1型糖尿病」と、生活習慣などが関与する「2型糖尿病」に分類されています. 日本人では90%以上が「2型糖尿病」に分類されており、食生活・運動不足・肥満等が原因で、以下の理由で引き起こされると考えられています.インスリンの分泌低下：インスリン量が減っているインスリンの抵抗性増大：インスリンの効きが悪くなっている 糖尿病の治療糖尿病治療はを基本としますが、最も大切なのは食事療法と運動療法です.1) 食事/運動療法を2～3カ月続けても血糖値が下がらない場合、薬物療法が開始されます. 糖尿病治療薬糖尿病治療薬にはいくつかの種類があり、年齢や肥満の程度、合併症、肝・腎機能等によって使い分けられます.まずは経口血糖降下薬の少量から開始されることが多いです.1) 経口血糖降下薬には以下の種類があり、糖尿病の原因(インスリン分泌低下、抵抗性増大)によって使い分けられます. ＜インスリン分泌低下を改善＞スルホニル尿素(SU)薬：インスリン分泌促進グリニド薬：より速やかなインスリン分泌促進DPP-4阻害薬：GLP-1分解抑制によるインスリン分泌促進とグルカゴン分泌抑制 ＜インスリン抵抗性を改善＞ビグアナイド薬：糖新生の抑制チアゾリジン薬：インスリンの感受性を向上 加えて、ブドウ糖の吸収を抑制する「α-グルコシダーゼ阻害薬」や、ブドウ糖の排泄を促進する「SGLT2阻害薬」等も使用されます. これら経口血糖降下薬を使用しても血糖値が下がらない場合、経口薬の増量や併用、そして注射剤(GLP-1受容体作動薬、インスリン製剤)の使用が検討されます. また、最近では経口血糖降下薬でコントロール不十分な場合、BOTやBPTと呼ばれれる治療が行われることもあります.持続型インスリン製剤＋経口血糖降下薬：BOT(Basal Supported Oral Therapy)持続型インスリン製剤＋GLP-1受容体作動薬：BPT(Basal supported post Prandial GLP-1 therapy)2) まずはBOTを行い、次いでBPTを行うといった流れですね. 新薬情報いずれもインスリン製剤は持続型の1日1回投与が主流ですので、簡便で外来治療でも導入しやすいと言われています. 今回ご紹介するゾルトファイは持続型インスリン製剤＋GLP-1受容体作動薬の配合剤のため、BPTに該当しますね. ゾルトファイ(インスリンデグルデク＋リラグルチド)の作用機序ゾルトファイはインスリン製剤とGLP-1受容体作動薬(GLP-1アナログ製剤)を配合した初の薬剤です.トレシーバ注 フレックスタッチ(インスリン デグルデク)：持続型インスリン製剤ビクトーザ皮下注(リラグルチド)：GLP-1受容体作動薬 インスリンデグルデクは持続的なインスリン作用を有し、1日1回の投与で特にピークもなく持続的に緩やかな血糖降下作用を示します. また、リラグルチドはGLP-1のアミノ酸配列を改変させてDPP-4の分解を受けにくくしたGLP-1受容体作動薬に分類されています.別名、「GLP-1アナログ製剤」とも呼ばれています(アナログとは""類似の""という意味です). 従って、投与されると生体内で長時間作用するのが特徴です.GLP-1は血糖値が低い時にはインスリンの分泌を促進しないため、生体内に長時間滞留しても低血糖になる恐れがありません. このようにゾルトファイは持続的インスリン製剤とGLP-1受容体作動薬の作用を併せ持ち、BPTとして血糖降下作用を示す薬剤ですね. ちなみに、GLP-1受容体作動薬は胃排泄遅延と食欲抑制によって、体重減少効果も示唆されています. 余談：GLP-1の発見アメリカドクトカゲと呼ばれるトカゲが、小動物を大量に捕食しても血糖値が全然上昇しないことがきっかけで、体内を調べたところ、ヒトのGLP-1によく似たGLP-1アナログが発見されたようです. エビデンス紹介：DUALⅠ試験根拠となった臨床試験はいくつかありますが、代表的なDUALⅠ試験をご紹介します.3)本試験は成人の2型糖尿病患者さん(メトホルミン±ピオグリタゾンによる既治療歴あり)を対象に、トレシーバとビクトーザとゾルトファイを比較する海外の第Ⅲ相臨床試験です. 主要評価項目は「26週時点のHbA1cのベースラインからの平均変化量」とされ、トレシーバに対するゾルトファイの非劣性、ビクトーザに対するゾルトファイの優越性を検証しました.試験群トレシーバゾルトファイビクトーザ26週時点のHbA1cの ベースラインからの平均変化量-1.4%-1.9%-1.3%差：-0.47%, 95% CI -0.58 to -0.36 非劣性が証明(p&lt;0.0001)--差：-0.64%, 95% CI -0.75 to -0.53 優越性が証明(p&lt;0.0001) 新薬情報ゾルトファイはトレシーバに対して非劣性、ビクトーザに対して優越性が証明されていますね. 副作用後日更新予定です. 用法・用量、在宅自己注射後日更新予定です.前述の臨床試験3)では1日1回投与されていました. ゾルトファイはフレックスタッチのため、プレフィルド製剤です. 新薬情報皮下投与のため在宅自己注射が可能になっていくものと予想されます. 薬価現時点では未承認かつ薬価未収載です. まとめ・あとがきゾルトファイはこんな薬持続型インスリン製剤とGLP-1受容体作動薬を配合した初の薬剤BPT治療として期待1日1回の投与で治療が可能 実地臨床でもしばしば持続型インスリン製剤とGLP-1受容体作動薬の併用が行われるため、ゾルトファイによって1剤にまとめられることは患者さんにとっても簡便化に繋がるのではないでしょうか. 以上、今回は糖尿病とゾルトファイ配合注フレックスタッチの作用機序、エビデンス等について解説しました! 糖尿病治療薬関連の以下のまとめ記事もありますので是非ご覧くださいませ☆ ★おススメの関連記事★ 薬剤師さんに自信を持っておススメできます!＼ 業務に活かせる ／ こんな情報を配信!薬局で使える行動心理学を紹介マネジメントスキルの解説役立つセミナー情報の配信成功している薬剤師・薬局さんのインタビュー服薬指導、接客、職場の人間関係のヒントになる無料のメールマガジンです.私も拝読していますが、なかなか普段の業務では知れない内容が多くて面白いですよ(特に行動心理学).是非薬剤師のあなたも覗いてみてくださいね.|ω・`)現場薬剤師のための課外授業",https://t.co/bwWsSzpRWn,others
"Long-Term Treatment With the Dipeptidyl Peptidase IV Inhibitor P32/98 Causes Sustained Improvements in Glucose Tolerance, Insulin Sensitivity, Hyperinsulinemia, and β-Cell Glucose Responsiveness in VDF (fa/fa) Zucker Rats | Diabetes","AbstractThe incretins, glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide 1 (GLP-1) are responsible for &gt;50% of nutrient-stimulated insulin secretion. After being released into the circulation, GIP and GLP-1 are rapidly inactivated by the circulating enzyme dipeptidyl peptidase IV (DP IV). The use of DP IV inhibitors to enhance these insulinotropic hormonal axes has proven effective on an acute scale in both animals and humans; however, the long-term effects of these compounds have yet to be determined. Therefore, we carried out the following study: two groups of fa/fa Zucker rats (n = 6 each) were treated twice daily for 3 months with the DP IV inhibitor P32/98 (20 mg · kg−1 · day−1, p.o.). Monthly oral glucose tolerance tests (OGTTs), performed after drug washout, revealed a progressive and sustained improvement in glucose tolerance in the treated animals. After 12 weeks of treatment, peak OGTT blood glucose values in the treated animals averaged 8.5 mmol/l less than in the controls (12.0 ± 0.7 vs. 20.5 ± 1.3 mmol/l, respectively). Concomitant insulin determinations showed an increased early-phase insulin response in the treated group (43% increase). Furthermore, in response to an 8.8 mmol/l glucose perfusion, pancreata from controls showed no increase in insulin secretion, whereas pancreata from treated animals exhibited a 3.2-fold rise in insulin secretion, indicating enhanced β-cell glucose responsiveness. Also, both basal and insulin-stimulated glucose uptake were increased in soleus muscle strips from the treated group (by 20 and 50%, respectively), providing direct evidence for an improvement in peripheral insulin sensitivity. In summary, long-term DP IV inhibitor treatment was shown to cause sustained improvements in glucose tolerance, insulinemia, β-cell glucose responsiveness, and peripheral insulin sensitivity, novel effects that provide further support for the use of DP IV inhibitors in the treatment of diabetes.In 1995, Kieffer et al. (1) showed glucose-dependent insulinotropic polypeptide-(1–42) (GIP) and glucagon-like peptide 1-(-36)amide (GLP-1) to be substrates of the circulating enzyme dipeptidyl peptidase IV (DP IV) in vivo. DP IV is an ubiquitous ectopeptidase that preferentially cleaves oligopeptides with a penultimate prolyl, alanyl, or seryl residue at the NH2-terminus, a substrate specificity that encompasses a number of bioactive peptides including GIP, GLP-1, and the counterregulatory hormone glucagon (2,3). DP IV−mediated cleavage of GIP and GLP-1 is a rapid process, yielding a circulating half-life of 1–2 min for the parent peptides. The resultant NH2-terminally truncated products GIP3–42 and GLP-19–36amide have been shown in a number of studies to be inactive at the receptor level and thus noninsulinotropic (4,5). Subsequent studies have clearly established DP IV−mediated NH2-terminal truncation as the primary mechanism for GIP and GLP-1 inactivation (1,6–8).Also known as the incretins, GIP and GLP-1 make up the endocrine component of the entero-insular (gut-pancreas) axis—a concept describing the neural, endocrine, and substrate signaling pathways between the small intestine and the islets of Langerhans (9). Together, the incretins are responsible for &gt;50% of nutrient-stimulated insulin release. In addition, the incretins share a number of non-insulin-mediated effects that contribute to effective glucose homeostasis. GIP and GLP-1 have both been shown to inhibit gastric motility and secretion (10,11), promote β-cell glucose competence (12), and stimulate insulin gene transcription and biosynthesis (13,14). In addition, GIP has been reported to play a role in the regulation of fat metabolism (15), and GLP-1 has been shown to stimulate β-cell differentiation and growth (16), as well as to restore islet-cell glucose responsiveness (17).We have previously shown that acute administration of the specific DP IV inhibitor P32/98 (isoleucyl-thiazolidine) in Zucker rats enhances insulin secretion and glucose tolerance (18), improvements that were much more profound in the diabetic, fatty animals than in their lean littermates (19). Balkan et al. (20) confirmed these findings using the DP IV inhibitor NVP-DPP728 and went on to provide evidence for the previously postulated stabilization of, and rise in, plasma active GLP-17–36 (GLP-1a) after inhibitor treatment. However, despite its efficacy, the use of DP IV inhibitors on an acute scale is unlikely to exploit the longer term incretin actions involving altered intracellular protein function and gene expression. It was therefore hypothesized that chronic DP IV inhibitor treatment of diabetic animals, in addition to improving glucose tolerance, would enhance β-cell glucose responsiveness, replication, and turnover, and thus result in sustained improvements in β-cell function.In the present study, two groups of Vancouver diabetic fatty (VDF) rats were treated for 3 months with the DP IV inhibitor P32/98. VDF rats are a substrain of the fatty (fa/fa) Zucker rat, which display abnormalities characteristic of type 2 diabetes, including mild hyperglycemia, hyperinsulinemia, glucose intolerance, hyperlipidemia, impaired insulin secretion, and peripheral and hepatic insulin resistance (21). Parameters including body weight, food and water intake, and oral glucose tolerance were regularly examined to track the progression of the disease and study the possible therapeutic effects of the inhibitor. At the end of the treatment period, ex vivo fat and muscle insulin sensitivity were assessed, and pancreas perfusion was performed to measure β-cell glucose responsiveness. The results provided the first demonstration that long-term DP IV inhibitor treatment causes progressive and sustained improvements in glucose tolerance, insulin sensitivity, and β-cell glucose responsiveness.RESEARCH DESIGN AND METHODSMaterials.The DP IV inhibitor P32/98 (di-[2S,3S]-2-amino-3-methyl-pentanoic-1,3-thiazolidine fumarate) was synthesized, as previously described (22).Animals.We randomly assigned six pairs of male fatty (fa/fa) VDF Zucker rat littermates to a control or treatment (P32/98) group at 440 g body wt (age 11 ± 0.5 weeks). Animals were housed on a 12-h light/dark cycle (lights on at 0600) and allowed access to standard rat diet and water ad libitum. The techniques used in this study were in compliance with the guidelines of the Canadian Council on Animal Care and were approved by the University of British Columbia Council on Animal Care, Certificate # A99-006.Protocol for daily monitoring and drug administration.The treatment group received P32/98 (10 mg/kg) by oral gavage twice daily (0800 and 1700) for 100 days, and the control animals received concurrent doses of vehicle consisting of a 1% cellulose solution. Every 2 days, body weight, morning and evening blood glucose, and food and water intake were assessed. Blood samples were acquired from the tail, and glucose was measured using a SureStep analyzer (Lifescan Canada, Burnaby, Canada). Food and water intake were measured by subtraction.Protocol for monthly assessment of glucose tolerance.Every 4 weeks from the start of the experiment, an oral glucose tolerance test (OGTT; 1 g/kg) was performed after an 18-h fast and complete drug washout (∼12 circulating half-lives for P32/93). No 0800 dose was administered in this case. Blood samples (250 μl) were collected from the tail using heparinized capillary tubes, centrifuged, and stored at −20°C. In the case of the 12-week OGTT, blood was collected directly into tubes containing the DP IV inhibitor P32/98 (final concentration 10 μmol/l) for analysis of active GLP-1 (EGLP-35K; Linco Research, St. Charles, MO). Plasma insulin was measured by radioimmunoassay using a guinea pig anti-insulin antibody (GP-01), as previously described (23), and blood glucose was measured as described above. Plasma DP IV activity was determined using a colorimetric assay measuring the liberation of p-nitroanilide (A405 nm) from the DP IV substrate H-gly-pro-pNA (Sigma; Parkville, Ontario, Canada). It is important to note that the assay involves a 20-fold sample dilution and therefore underestimates the actual degree of inhibition occurring in the undiluted sample when using rapidly reversible inhibitors such as P32/98.Estimations of insulin sensitivity made from OGTT data were performed using the composite insulin sensitivity index proposed by Matsuda and DeFronzo (24). Calculation of the index was made according to the following equation: where FPG and FPI are fasting plasma glucose and insulin concentrations, respectively, and MG and MI are the mean glucose and insulin concentrations, respectively, over the course of the OGTT.Protocol for 24-h glucose, insulin, and DP IV profile.To determine the effects of DP IV inhibition over a 24-h period, blood glucose, insulin, and DP IV activity levels were measured as described above, every 3 h for 24 h, 6 weeks into the study. Drug dosing was continued at the appropriate times during the profile.Skeletal muscle insulin sensitivity.Uptake of 14C-labeled glucose in soleus muscle strips was measured as an indicator of skeletal muscle insulin sensitivity. In brief, after an overnight fast and 18 h after the last dose of P32/98, the animals were anesthetized with pentobarbital sodium (Somnotol; ∼50 mg/kg). The soleus muscles of both hindlimbs were exposed and isolated. After freeing the muscle by severing the proximal and distal tendons, strips of ∼25–35 mg were pulled from the muscle (the two outer thirds of each muscle were used). After being weighed, the strips were fixed onto stainless steel clips at their resting length and allowed to stabilize for 30 min in a Krebs-Ringer bicarbonate buffer supplemented with 3 mmol/l pyruvate, continuously gassed with 95% O2:5% CO2 and held at 37°C in a shaking water bath. These conditions were maintained for the duration of the experiment, unless otherwise stated.To assess glucose uptake in response to insulin, muscle strips underwent two preincubations (30 and 60 min) followed by a 30-min test incubation. Both the second preincubation and the test incubation contained 0 or 800 μU/ml insulin. The test incubation was performed in media supplemented with [3H]inulin (0.1 μCi/ml) as a measure of extracellular space and the nonmetabolizable glucose analogue [14C]-3-O-methylglucose (0.05 μCi/ml) for measurement of glucose uptake. After incubation, each strip was blotted dry and digested with proteinase K (0.25 μg/ml), and the radioactivity of the muscle digests was measured with a liquid scintillation−counting dual-isotopic program.Adipose tissue insulin sensitivity.To estimate insulin sensitivity in adipose tissue, glycogen synthase (GS) and acetyl-CoA carboxylase (ACC) levels were measured, as previously described (25,26). In brief, 3-cm3 samples of ependymal adipose tissue were obtained from anesthetized animals and subjected to a 16-min collagenase digestion (0.5 mg/ml). Recovered adipocytes were washed three times and allowed to stabilize for 1 h in 37°C Krebs buffer repetitively gassed with 95% O2:5% CO2. Then 2-ml aliquots of the adipocyte suspension containing 0, 100, 250, 800, and 1,500 μU/ml insulin were incubated for 30 min and immediately flash frozen on liquid nitrogen and stored at −70°C. Before ACC and GS assessment, stored samples were thawed, homogenized in buffer (pH 7.2) containing 20 mmol/l MOPS, 250 mmol/l sucrose, 2 mmol/l EDTA, 2 mmol/l EGTA, 2.5 mmol/l benzamidine, and centrifuged (15 min at 15,000g).For measurement of ACC activity, 50-μl aliquots of supernatant, preincubated in the presence or absence of 20 mmol/l citrate, were added to 450 μl of [14C]HCO3 containing assay buffer (pH 7.4; 50 mmol/l HEPES, 10 mmol/l MgSO4, 5 mmol/l EDTA, 5.9 mmol/l ATP, 7.8 mmol/l glutathione, 2 mg/ml BSA, 15 mmol/l KHCO3, 150 μmol/l acetyl CoA). After 3 min, the reaction was arrested by the addition of 200 μl of 5 mol/l HCl. Samples were dried for 6 h, resuspended in 400 μl of distilled water, combined with 3 ml scintillation cocktail, and counted on a Beckman LS 6001C β-counter.GS activity was measured using a modification of a filter paper method (26): 25 μl of the cell extracts, prepared as indicated above, were added to assay buffer (pH 7.0; 75 mmol/l MOPS, 75 mmol/l NaF, 10 mg/ml glycogen, 2 mmol/l UDP-[14C]glucose) held at 30°C in the presence or absence of 15 mmol/l glucose-6-phosphate. Each reaction was stopped by spotting 50 μl of the reaction mixture onto Whatmann 3MM filter paper and immersing the paper in 66% ethanol. After three ethanol washes, the samples were air dried and the [14C] activity (UDP-[14C]glucose incorporation into glycogen) was determined.Protocol for pancreas perfusion.After excision of soleus and ependymal adipose tissue samples, the pancreas was isolated and perfused with a low-to-high glucose (4.4 to 8.8 mmol/l) perfusion protocol, as previously described (27). After exposure through a mid-line incision on the ventral aspect, the pancreas was isolated, all minor vessels were ligated, and a glucose perfusate was introduced through the celiac artery. Perfusion effluent was collected at 1-min intervals via the portal vein, with a perfusion rate of 4 ml/min. Samples were stored at −20°C until analysis.Immunohistochemistry and β-cell mass determination.Pancreata were removed from anesthetized animals (50 mg/kg sodium pentobarbital) and placed directly into fixative for 48 h (44% formaldehyde, 47% distilled H2O, 9% glacial acetic acid). After being embedded in paraffin, 5-μm tissue sections were cut, mounted onto slides, and dried ready for staining. To assess β-cell area, sections were stained first with a guinea pig anti-insulin primary antibody and then with peroxidase-conjugated goat anti-guinea pig secondary. Slides were developed using diaminobenzidine and counterstained with hematoxylin. Analyses were performed using Northern Eclipse Software (Empix Imaging, Mississauga, Ontario, Canada), as previously described (28).Statistical Analysis.Student's t test and ANOVA were used, where appropriate, to test statistical significance of the data (P &lt; 0.05). Analyses were performed using Prism 3.0 data analysis software (GraphPad Software, San Diego, CA).RESULTSEffects of P32/98 treatment on body weight, daily blood glucose, and food and water intake.VDF rats treated with P32/98 displayed a 12.5% (25 g) reduction in weight gain over the 3-month treatment period (control: 211 ± 8 g; treated: 176 ± 6 g) (Fig. 1A). Measurements of food and water intake revealed a minor decrease in water intake (Fig. 1B) in the treated animals concomitant with unaltered food intake. Food intake over the course of the experiment averaged 30.0 ± 0.4 and 30.4 ± 0.3 g · rat−1 · day−1 in the treated and control groups, respectively. Food and water intake decreased over the course of the experiment, paralleling the decrease in the rate of weight gain as the growth of the animals began to plateau at around 600–650 g (data not shown). Twice-daily monitoring of blood glucose revealed no differences in morning or evening blood glucose values between the experimental groups, although neither group displayed notably hyperglycemic values (data not shown). Morning blood glucose levels over the course of the experiment averaged 5.0 ± 0.1 and 5.3 ± 0.1 mmol/l in the treated and control animals, respectively. Evening blood glucose values averaged 6.7 ± 0.1 and 7.0 ± 0.2 mmol/l, respectively. Hematocrit, measured at 4-week intervals, indicated no adverse effects of the blood-sampling protocol used, averaging 43.4–45.3% in both groups.Effects of P32/98 treatment on blood glucose, insulin, and DP IV levels over 24 h.After 6 weeks of treatment, a 24-h profile of blood glucose, insulin, and DP IV activity levels was obtained by taking blood samples at 3-h intervals, interrupting neither treatment administration nor the light/dark cycle. The profile confirmed that administration of P32/98 caused significant inhibition of DP IV activity over the majority of the 24-h cycle, with at least 65% inhibition during the feeding cycle (Fig. 2A). The integrated blood glucose excursion in the treated animals was 75% that of the controls, peaking at 7.7 ± 0.3 mmol/l, as compared to 9.8 ± 0.6 mmol/l for the untreated animals (Fig. 2B). The corresponding plasma insulin profile showed a decrease not only in peak insulin values, but also in ""basal,"" nonfeeding values (∼0800 to 1800) in the treated animals (Fig. 2C).Effects of P32/98 treatment on oral glucose tolerance.The three OGTTs, performed in the absence of circulating P32/98 and at 1-month intervals, were used to monitor the progression of the disease state in the control animals and to document any improvements displayed in the treated group. The initial OGTT, administered after 4 weeks of treatment, showed significant decreases (∼2 mmol/l) in basal and 45-, 60-, and 90-min blood glucose values in the treated group, despite overlapping plasma insulin excursions (Fig. 3A). Data from the second OGTT were very similar, with the exception that the 120-min blood glucose value was also significantly lowered in the treated group than in the control group (10.8 ± 0.8 vs. 12.3 ± 0.8, respectively); once again, the insulin profiles were superimposable (data not shown). The final OGTT, performed after 12 weeks of treatment, showed a marked difference in glucose tolerance between the two groups, with significantly decreased blood glucose values observed at all time points. Peak blood glucose values in the treated group averaged 12.0 ± 0.7 mmol/l, 8.5 mmol/l less than that of control animals (Fig. 3B), whereas 2-h values in the treated group had returned to 9.2 ± 0.5 mmol/l, a 40% reduction compared to control values. GLP-1a levels, measured during the final OGTT using an NH2-terminally directed enzyme-linked immunosorbent assay, were found to be unchanged (Fig. 3B). Despite this lack of altered GLP-1a levels, the early-phase insulin response measured in the treated group exceeded that of the control animals by 43%. However, the integrated insulin responses between the two groups showed no significant differences. Analysis of the OGTT data using the composite insulin sensitivity index of Matsuda and DeFronzo (24) revealed a progressive increase in estimated insulin sensitivity of the treated animals relative to controls (Fig. 3C).Comparison of the OGTTs over the course of the experiment revealed a progressive decrease in both fasting and peak blood glucose values in animals treated with P32/98, improvements that were not observed in control animals (Figs. 4A and B). Peak insulin values did not differ significantly between the two experimental groups until the final, 12-week, OGTT, at which time the peak insulin levels in the treated animals exceeded those of the control animals by an average of 43% (Fig. 4C). Plasma DP IV activity, measured at the start of each OGTT, was significantly increased in the treated group by week 8 of the study, and the elevation was maintained at week 12 (Fig. 4D).Effects of chronic DP IV inhibitor treatment on pancreatic glucose responsiveness.A low-to-high step glucose perfusion protocol was performed on the pancreata of half of each group of animals. The shift from 4.4 to 8.8 mmol/l glucose perfusate caused a 3.2-fold increase in insulin secretory rate in the pancreata from the treated animals (Fig. 5). The insulin secretory rate shifted from a basal 570 ± 170 to over 2,100 μU/min within 2 min of high glucose perfusion. The same glucose step procedure failed to elicit any significant response in the control pancreata until well over 20 min of high glucose perfusion (Fig. 5).Effects of chronic DP IV inhibitor treatment on muscle and fat insulin sensitivity.To further define the apparent improvements in insulin sensitivity observed in the OGTT data, assays of muscle and fat insulin sensitivity were performed. GS and ACC activity were measured in isolated adipocytes along with uptake of 14C-labeled glucose into soleus muscle strips. ACC levels in adipose from both experimental groups were minimal (approaching limits of detection), lacked insulin responsiveness, and showed no differences between the two groups (data not shown). GS activity also appeared insensitive to insulin, although the activity of the enzyme at all measured insulin concentrations was higher in the treated animals than in their control littermates (Fig. 6A). Soleus muscle strips taken from the treated animals exhibited significantly higher rates of glucose uptake, in both the basal and the insulin-stimulated states. Glucose uptake in the nonstimulated state was 22% higher in the treated rats (Fig. 6B). The insulin-stimulated rise in glucose uptake was enhanced in the treated compared to in the control group (87.5 ± 10.4 vs. 58.5 ± 3.5 cpm/mg tissue at 800 μU/ml insulin, respectively).Effects of chronic DP IV inhibitor treatment on β-cell area and islet morphology.The 3-month oral DP IV inhibitor regimen yielded no significant differences in β-cell area or islet morphology. Islets from control and treated animals comprised 1.51 ± 0.04 and 1.50 ± 0.03% of the total pancreatic area, respectively. Large, irregularly shaped islets with significant β-cell hyperplasia were observed in both groups, a morphology characteristic of the fa/fa Zucker rat.DISCUSSIONThe use of DP IV inhibitors to enhance the entero-insular axis has attracted much recent interest as a potential therapeutic strategy in the treatment of diabetes. Several recent studies have established the efficacy of these compounds on an acute scale (18–20,29). However, investigations performed on an acute scale do not exploit the potential benefits of long-term incretin effects, such as the enhancement of β-cell glucose sensitivity and the stimulation of β-cell mitogenesis, differentiation, and insulin biosynthesis. Here we reported the results of the first study of long-term DP IV inhibitor treatment in a model of type 2 diabetes, the VDF fa/fa rat. The results demonstrated that long-term DP IV inhibition arrested the progression of the fa/fa Zucker diabetic syndrome and caused a progressive improvement in glucose tolerance, insulin sensitivity, and β-cell glucose responsiveness.Daily monitoring revealed a 12.5% decrease in body weight gain (4% reduction in final body weight) in the treated animals compared to untreated controls (Fig. 1A). Although not statistically significant, mean food intake in the treated animals averaged 0.4 g · day−1 · rat−1 (41 g/rat over the course of the study) less than those in the control group. The cumulative 41 g/rat nonsignificant difference in food intake over the course of the experiment might partially account for the decreased weight gain in the treated animals. These findings rule out neither the possibility that the gastric inhibitory actions of the incretins nor the reported satiety effects of GLP-1 played a role in the decrease in weight gain.Monitored every 2 days, morning and evening blood glucose values showed no significant response to the inhibitor treatment, a likely reflection of two points. First, the blood-sampling times (0800 and 1700) corresponded to postabsorptive and early feeding states, respectively, with blood glucose values in the ranges of 4.5–5.5 and 6.0–8.0 mmol/l, respectively. In light of the hypothesized, glucose-dependent mechanism of action of the treatment, large decreases in glucose values would not be anticipated at these glycemic levels. Second, both morning and evening blood samples were collected immediately before drug dosing, at times of minimum DP IV inhibition, when the potential for any acute therapeutic effects of the treatment were at a minimum. Both points are supported by the 24-h profile shown in Fig. 2.The unaltered postabsorptive blood glucose values notwithstanding, DP IV inhibitor treatment effectively reduced both prandial blood glucose and blood glucose responses to an OGTT (Figs. 2 and 3). During the 24-h profile, the control animals exhibited a 105% rise in plasma insulin in response to a 5.2-mmol/l increase in blood glucose, whereas the treated animals displayed a 160% insulin response to a much smaller glucose excursion (3.0 mmol/l). Although these differences were likely attributable, at least in part, to an acute increase in circulating incretin levels induced by P32/98, the pronounced early-phase insulin peak exhibited during the OGTT was not (the OGTT took place after complete drug washout). The latter data suggest not only an increased insulin sensitivity, but also an enhanced β-cell glucose responsiveness, in treated animals. Ultimately, an increase in β-cell glucose responsiveness was clearly demonstrated through pancreas perfusion. After exposure to an elevated (8.8 mmol/l) glucose perfusate, pancreata from the control animals showed an absence of first-phase insulin release, whereas those from the treated group exhibited an immediate 3.2-fold insulin response (Fig. 5). The absence of an early-phase insulin release seen in the control group is characteristic of the VDF rat and is a hallmark of type 2 diabetes (21). Considering the lack of altered β-cell area or islet morphology, these data suggest that long-term treatment with P32/98 causes an improvement in the ability of the existing β-cell population to sense and respond to increases in glucose concentration. These findings are consistent with the reported effects of GLP-1 on β-cell differentiation, as well as numerous reports showing the glucose-sensitizing effects of GIP and GLP-1 in both islets and immortalized β-cell models (30,31).Elevated fasting blood glucose in the face of hyperinsulinemia and poor clearance of an oral glucose load are consistent with the hepatic and muscle insulin resistance, respectively, described in the fa/fa Zucker rat. Findings in the present study showed that DP IV inhibitor treatment at least partially corrected both of these metabolic deviations, suggesting improvements in both sites of insulin resistance. An increased glucose-to-insulin ratio evident during the postabsorptive state of the 24-h profile (Fig. 2), as well as fasting values of the 12-week OGTT (Figs. 3 and 4), were consistent with a decrease in insulin resistance in the treated animals. The latter increase in insulin sensitivity was shown to be significant at both 4 and 12 weeks using the composite insulin sensitivity index of Matsuda and DeFronzo (24). This mathematical analysis was previously validated (with high correlation) against the hyperinsulinemic-euglycemic clamp technique in 153 subjects with varying degrees of insulin resistance. The relative insulin sensitivity of the treated animals improved with each successive OGTT, ultimately reaching a relative index score 1.56 ± 0.26 times that of the control animals. The results of the 24-h glucose/insulin/DP IV profile and the OGTT were corroborated by direct measurements of glucose uptake in soleus muscle strips, which clearly demonstrated improved glucose uptake in both the nonstimulated and the insulin-stimulated states (Fig. 6). Though somewhat controversial, both GIP and GLP-1 (and exendin-4) have been reported to increase muscle insulin sensitivity through the stimulation of glycogen synthesis and glucose uptake (32–35). In addition, a number of whole animal studies using GLP-1 or related GLP-1 receptor agonists have observed similar improvements in glucose tolerance and insulin sensitivity. Young et al. (36) showed that long-term administration of the GLP-1 agonist exendin-4 causes glucose-lowering and insulin-sensitizing effects in a number of diabetic animal models, including the fa/fa Zucker rat. Also, a number of subchronic infusion studies have revealed improvements in glycemic control, glucose tolerance, and insulin sensitivity (37–39). Our findings are consistent with the results of these previous investigations. However, the indirect contributions of a long-term improvement in glycemia or long-term enhancement of a number of other DP IV substrates (in particular, the insulin secretagogues vasoactive intestinal peptide, pituitary adenylyl cyclase-activating peptide, gastrin-releasing peptide, and neuropeptide Y) over the course of the treatment cannot be ruled out as a causative factor for the metabolic improvements observed. Further experiments will be required to address this issue and that of the relative effect of DP IV inhibitor therapy on each of the major insulin-sensitive tissues.An important facet shared by the OGTT, the muscle glucose uptake and the pancreas perfusion protocols, was that cessation of drug treatment occurred 18 h before these experimental procedures. Any divergence between groups, therefore, reflected long-term, lasting changes in metabolic state, rather than an acute effect of the drug. Drug washout was confirmed by DP IV activity measurements. It is interesting that an increase in DP IV activity was observed in the treated animals over the course of the study, which was likely a compensatory response to chronic inhibition of DP IV activity in the treated group (&gt;90% of the 24-h cycle). The significance of this finding is not fully understood, as the circulating, soluble form of DP IV measured in the present study represents only 5–10% of the entire DP IV pool (2). Therefore, further investigation into the effects of DP IV inhibitor therapy on other sources of DP IV activity in the circulation (particularly lymphocytic and endothelial DP IV) is warranted. It is likely that the compensatory change in circulating DP IV levels could be avoided by once-daily treatment and/or a lower inhibitor dosage. Therapeutic dosages required to improve glucose tolerance on an acute scale in humans (∼0.2 mg/kg) are 100-fold lower than those used in the present study (40,41).Several therapeutic strategies exploiting the antidiabetic effects of GIP and GLP-1 are currently being pursued. The success of DP IV inhibition is owed in part to a mechanism of action that impacts only a single physiological regulatory system. DP IV inhibition slows the rate of incretin inactivation, but leaves the nutrient-dependent mechanism of incretin release intact and the glucose dependence of their anti-diabetic actions unaltered. The present study showed for the first time that long-term DP IV inhibitor therapy leads to enhanced peripheral insulin sensitivity and β-cell glucose responsiveness, improvements that culminate in markedly improved glucose tolerance well beyond the clearance time of the drug. Further, the findings of this study exemplify the importance of the noninsulinotropic effects of GIP and GLP-1 in the regulation of β-cell function. In conclusion, the data presented here establish the potential utility of DP IV inhibitors in the treatment of diabetes.FIG. 1. Body weight and water intake measured in DP IV inhibitor−treated (○) or control (▪) VDF rats (n = 6 in each group). Body weight (A), and water intake (B) were measured along with morning and evening blood glucose levels and food intake (not shown) every 2 days. *P &lt; 0.05 vs. other group.FIG. 2. A 24-h profile of plasma DP IV activity (A), blood glucose (B), and plasma insulin (C) levels in VDF rats after 6 weeks of treatment, either with (○) or without (▪) the DP IV inhibitor P32/98 (n = 6 in each group). Treated animals were administered 10 mg/kg P32/98 twice daily, as indicated by the arrows, and whereas the control group received only the 1% cellulose injection vehicle. *P &lt; 0.05 vs. other group.FIG. 3. OGTT administered to both DP IV inhibitor−treated (○) and control (▪) VDF rats (n = 6 in each group) after 4 (A) and 12 (B) weeks of treatment. Blood glucose and plasma insulin measurements were performed in both series of tests, while the active fraction of plasma GLP-1 was also measured at 12 weeks. The inset in B shows the integrated plasma insulin responses for the 12-week OGTT. C: Relative insulin sensitivity, control versus treated, corresponding to the 4- and 12-week OGTTs shown in A and B. *P &lt; 0.05 vs. other group.FIG. 4. Comparison of fasting (A) and peak (B) blood glucose, peak plasma insulin (C), and fasting plasma DP IV activity (D) measured during OGTTs performed at 4-week intervals in control (▪) or DP IV inhibitor−treated (○) VDF rats (n = 6 in each group). *P &lt; 0.05 vs. other group.FIG. 5. Insulin release measured during perfusion of pancreata from VDF rats after 3 months of treatment with (○) or without (▪) the DP IV inhibitor P32/98 (n = 3 in each group).FIG. 6. Adipose tissue glycogen synthase activity (A) and uptake of 3-O-[14C] methyl-d-glucose into soleus muscle strips (B) isolated from VDF rats after 12 weeks of P32/98 treatment (□) or a control 1% cellulose solution (▪) (n = 6 in each group). *P &lt; 0.05 vs. corresponding control value; †P &lt; 0.01 vs. corresponding control value; ‡statistically significant difference from basal ([insulin] = 0 μU/ml).AcknowledgmentsThis study was supported by grants from the Canadian Diabetes Association, the Canadian Institute for Health Research (CIHR), and Probiodrug J.A.P. is grateful to the CIHR, Michael Smith Foundation for Health Research, and the Killam Trust Foundation for scholarship support.We would like to thank Cuilan Nian, Narinder Dhatt, and Susan Collins for their excellent technical support.FootnotesAddress correspondence and reprint requests to Dr. R.A. Pederson, Department of Physiology, University of British Columbia, 2146 Health Sciences Mall, Vancouver, BC, Canada V6T 1Z3. E-Mail: pederson{at}interchange.ubc.ca.Received for publication 28 August 2001 and accepted in revised form 9 January 2002.ACC, acetyl-CoA carboxylase; DP IV, dipeptidyl peptidase IV; GIP, glucose-dependent insulinotropic polypeptide-(1–42); GLP-1, glucagon-like peptide 1-(7-36)amide; GLP-1a, active GLP-17–36; GS, glycogen synthase; OGTT, oral glucose tolerance test.H.-U.D. is the Chief Executive Officer and Chief Scientific Officer of and a shareholder in Probiodrug GmbH, a pharmaceutical company in the process of developing a DP IV inhibitor treatment for diabetes and its complications. R.A.P. and C.H.S.M. are both members of a scientific advisory panel to Probiodrug and receive consulting fees for their participation. R.A.P. and C.H.S.M. also receive grant/research support from Probiodrug to support studies on the drug candidate P32/98 and its utility in treating diabetes and its complications.DIABETESREFERENCES↵Kieffer TJ, McIntosh CH, Pederson RA: Degradation of glucose-dependent insulinotropic polypeptide and truncated glucagon-like peptide 1 in vitro and in vivo by dipeptidyl peptidase IV.Endocrinology136:3585–3596,1995↵Mentlein R: Dipeptidyl-peptidase IV (CD26): role in the inactivation of regulatory peptides.Regul Pept85:9–24,1999↵Pospisilik JA, Hinke SA, Pederson RA, Hoffmann T, Rosche F, Schlenzig D, Glund K, Heiser U, McIntosh CH, Demuth H: Metabolism of glucagon by dipeptidyl peptidase IV (CD26).Regul Pept96:133–141,2001↵Suzuki S, Kawai K, Ohashi S, Mukai H, Yamashita K: Comparison of the effects of various C-terminal and N-terminal fragment peptides of glucagon-like peptide-1 on insulin and glucagon release from the isolated perfused rat pancreas.Endocrinology125:3109–3114,1989↵Schmidt W, Siegel E, Ebert R, Creuzfeldt W: N-terminal tyrosine-alanine is required for the insulin releasing activity of glucose-dependent insulinotropic polypeptide (GIP).Eur J Clin Invest16:A9,1986↵Pauly RP, Rosche F, Wermann M, McIntosh CH, Pederson RA, Demuth HU: Investigation of glucose-dependent insulinotropic polypeptide-(1–42) and glucagon-like peptide-1-(7–36) degradation in vitro by dipeptidyl peptidase IV using matrix-assisted laser desorption/ionization-time of flight mass spectrometry: a novel kinetic approach.J Biol Chem271:23222–23229,1996Deacon CF, Nauck MA, Meier J, Hucking K, Holst JJ: Degradation of endogenous and exogenous gastric inhibitory polypeptide in healthy and in type 2 diabetic subjects as revealed using a new assay for the intact peptide.J Clin Endocrinol Metab85:3575–3581,2000↵Hansen L, Deacon CF, Orskov C, Holst JJ: Glucagon-like peptide-1-(7–36)amide is transformed to glucagon-like peptide-1-(9–36)amide by dipeptidyl peptidase IV in the capillaries supplying the L cells of the porcine intestine.Endocrinology140:5356–5363,1999↵Unger RH, Eisentraut AM: Entero-insular axis.Arch Intern Med123:261–266,1969↵Schirra J, Katschinski M, Weidmann C, Schafer T, Wank U, Arnold R, Goke B: Gastric emptying and release of incretin hormones after glucose ingestion in humans.J Clin Invest97:92–103,1996↵Pederson RA, Brown JC: Inhibition of histamine-, pentagastrin-, and insulin-stimulated canine gastric secretion by pure ""gastric inhibitory polypeptide"".Gastroenterology62:393–400,1972↵Huypens P, Ling Z, Pipeleers D, Schuit F: Glucagon receptors on human islet cells contribute to glucose competence of insulin release.Diabetologia43:1012–1009,2000↵Fehmann H-C, Habener JF: Insulinotropic hormone glucagon-like peptide-1(7–37) stimulation of proinsulin gene expression and proinsulin biosynthesis in insulinoma beta TC-1 cells.Endocrinology130:159–166,1992↵Drucker DJ, Philippe J, Mojsov S, Chick WL, Habener JF: Glucagon-like peptide I stimulates insulin gene expression and increases cyclic AMP levels in a rat islet cell line.Proc Natl Acad Sci U S A84:3434–3438,1987↵Pederson R: Gastric inhibitory polypeptide. InGut Peptides. Walsh JH, Dockray GJ, Eds. New York, Raven Press,1994, p.217–259↵Hui H, Wright C, Perfetti R: Glucagon-like peptide 1 induces differentiation of islet duodenal homeobox-1-positive pancreatic ductal cells into insulin-secreting cells.Diabetes50:785–796,2001↵Zawalich WS, Zawalich KC, Rasmussen H: Influence of glucagon-like peptide-1 on beta cell responsiveness.Regul Pept44:277–283,1993↵Pauly R, Demuth H-U, Rosche F, Schmidt J, White H, McIntosh C, Pederson R: Inhibition of dipeptidyl peptidase IV (DP IV) in rat results in improved glucose tolerance (Abstract).Regul Pept64:148,1996↵Pederson RA, White HA, Schlenzig D, Pauly RP, McIntosh CH, Demuth HU: Improved glucose tolerance in Zucker fatty rats by oral administration of the dipeptidyl peptidase IV inhibitor isoleucine thiazolidide.Diabetes47:1253–1258,1998↵Balkan B, Kwasnik L, Miserendino R, Holst JJ, Li X: Inhibition of dipeptidyl peptidase IV with NVP-DPP728 increases plasma GLP-1 (7–36 amide) concentrations and improves oral glucose tolerance in obese Zucker rats.Diabetologia42:1324–1331,1999↵Lynn FC, Pamir N, Ng EH, McIntosh CH, Kieffer TJ, Pederson RA: Defective glucose-dependent insulinotropic polypeptide receptor expression in diabetic fatty Zucker rats.Diabetes50:1004–1011,2001↵Demuth HU: Recent developments in inhibiting cysteine and serine proteases.J Enzyme Inhib3:249–278,1990↵Jia X, Elliott R, Kwok YN, Pederson RA, McIntosh CH: Altered glucose dependence of glucagon-like peptide I(7–36)-induced insulin secretion from the Zucker (fa/fa) rat pancreas.Diabetes44:495–500,1995↵Matsuda M, DeFronzo RA: Insulin sensitivity indices obtained from oral glucose tolerance testing: comparison with the euglycemic insulin clamp.Diabetes Care22:1462–1470,1999↵Brownsey RW, Denton RM: Evidence that insulin activates fat-cell acetyl-CoA carboxylase by increased phosphorylation at a specific site.Biochem J202:77–86,1982↵Thomas JA, Schlender KK, Larner J: A rapid filter paper assay for UDP-glucose-glycogen glucosyltransferase, including an improved biosynthesis of UDP-14C-glucose.Anal Biochem25:486–499,1968↵Pederson RA, Buchan AM, Zahedi-Asl S, Chan CB, Brown JC: Effect of jejunoileal bypass in the rat on the enteroinsular axis.Regul Pept5:53–63,1982↵Finegood DT, McArthur MD, Kojwang D, Thomas MJ, Topp BG, Leonard T, Buckingham RE: Beta-cell mass dynamics in Zucker diabetic fatty rats: rosiglitazone prevents the rise in net cell death.Diabetes50:1021–1029,2001↵Ahren B, Holst JJ, Martensson H, Balkan B: Improved glucose tolerance and insulin secretion by inhibition of dipeptidyl peptidase IV in mice.Eur J Pharmacol404:239–245,2000↵Wang Y, Montrose-Rafizadeh C, Adams L, Raygada M, Nadiv O, Egan JM: GIP regulates glucose transporters, hexokinases, and glucose-induced insulin secretion in RIN 1046-38 cells.Mol Cell Endocrinol116:81–87,1996↵Wang Y, Egan JM, Raygada M, Nadiv O, Roth J, Montrose-Rafizadeh C: Glucagon-like peptide-1 affects gene transcription and messenger ribonucleic acid stability of components of the insulin secretory system in RIN 1046-38 cells.Endocrinology136:4910–4917,1995↵Yang H, Egan JM, Wang Y, Moyes CD, Roth J, Montrose MH, Montrose-Rafizadeh C: GLP-1 action in L6 myotubes is via a receptor different from the pancreatic GLP-1 receptor.Am J Physiol275:C675–C683,1998O'Harte FP, Abdel-Wahab YH, Conlon JM, Flatt PR: Amino terminal glycation of gastric inhibitory polypeptide enhances its insulinotropic action on clonal pancreatic B-cells.Biochim Biophys Acta1425:319–327,1998Mizuno A, Kuwajima M, Ishida K, Noma Y, Murakami T, Tateishi K, Sato I, Shima K: Extrapancreatic action of truncated glucagon-like peptide-I in Otsuka Long-Evans Tokushima Fatty rats, an animal model for non-insulin-dependent diabetes mellitus.Metabolism46:745–749,1997↵Alcantara AI, Morales M, Delgado E, Lopez-Delgado MI, Clemente F, Luque MA, Malaisse WJ, Valverde I, Villanueva-Penacarrillo ML: Exendin-4 agonist and exendin(9–39)amide antagonist of the GLP-1(7- 36)amide effects in liver and muscle.Arch Biochem Biophys341:1–7,1997↵Young AA, Gedulin BR, Bhavsar S, Bodkin N, Jodka C, Hansen B, Denaro M: Glucose-lowering and insulin-sensitizing actions of exendin-4: studies in obese diabetic (ob/ob, db/db) mice, diabetic fatty Zucker rats, and diabetic rhesus monkeys (Macaca mulatta).Diabetes48:1026–1034,1999↵Freyse EJ, Becher T, El-Hag O, Knospe S, Göke B, Fischer U: Blood glucose lowering and glucagonostatic effects of glucagon-like peptide I in insulin-deprived diabetic dogs.Diabetes46:824–828,1997Larsen J, Jallad J, Damsbo P: One week continuous infusion of GLP-1 (7–37) improves glycemic control in NIDDM (Abstract).Diabetes45:233A,1996↵Rachman J, Barrow B, Levy J, Turner R: Near normalisation of diurnal glucose concentrations by continuous administrations of glucagon-like peptide-1 (GLP-1) in subjects with NIDDM.Diabetologia40:205–211,1997↵Demuth H-U, Hoffmann T, Glund K, McIntosh CHS, Pederson RA, Fuecker K, Fischer S, Hanefeld M: Single dose treatment of diabetic patients by the inhibitor P32/98 (Abstract).Diabetes49 (Suppl. 1):A102,2000↵Glund K, Hoffmann T, Demuth H-U, Banke-Bochita J, Rost KL, Fuder H: Single dose-escalation study to investigate the safety and tolerability of the DP IV inhibitor P32/98 in healthy volunteers (Abstract).Exp Clin Endocrinol Diabetes108:159,2000",https://t.co/W0uZ03vj3h,others
Glucagon-like Peptide 2 - a Glucose Dependent Glucagonotropic Hormone?,"OverviewInfusion of glucagon-like peptide 2 (GLP-2) during euglycaemia, hypoglycaemia and hyperglycaemia and evaluation of the effect on glucagon secretion in healthy subjects.Full Title of Study: ""Glucagon-like Peptide 2 – a Glucose Dependent Glucagonotropic Hormone?""Study TypeStudy Type: InterventionalStudy DesignAllocation: RandomizedIntervention Model: Crossover AssignmentPrimary Purpose: Basic ScienceMasking: Double (Participant, Investigator)Study Primary Completion Date: May 29, 2019Detailed DescriptionThis is a cross-over, randomized, double-blinded study in which 10 participants will undergo 6 experimental days each. The participants will have their plasma glucose clamped at either euglycaemia (fasting level), hypoglycemia (2,5 mmol/l) or hyperglycemia (10 mmol/l) during infusion of GLP-2 or saline (placebo)The six days will be as follows:- Euglycaemia + Placebo- Euglycaemia + GLP-2- Hyperglycaemia + Placebo- Hyperglycaemia + GLP-2- Hypoglycaemia + Placebo- Hypoglycaemia + GLP-2The primary endpoint will be levels of plasma glucagon. Secondary endpoint will be levels of GLP-1, GLP-2, Insulin/C-peptide, OXM, Amino acids, CCK, Gastrin, norepinephrine, bile acids, FGF-19/FGF-21. Secondary endpoints will also include ultrasound scan of the gallbladder.InterventionsOther: Glucagon-like peptide 2Human glucagon-like peptide 2Other: SalineOther: Glucose20% (w/v) glucose infusion for regulating plasma glucoseOther: InsulinActrapid (insulin) for lowering plasma glucoseArms, Groups and CohortsExperimental: Hyperglycaemia + GLP-2Active Comparator: Hyperglycaemia + PlaceboExperimental: Hypoglycaemia + GLP-2Insulin + glucose + GLP-2Active Comparator: Hypoglycaemia + SalineExperimental: Euglycaemia + GLP-2Active Comparator: Euglycaemia + PlaceboClinical Trial Outcome MeasuresPrimary MeasuresGlucagon secretionTime Frame: 120 minMeasured in pmol/literSecondary MeasuresPlasma glucoseTime Frame: 120 minMeasured in mmol/literGLP-1Time Frame: 120 minGlucagon-like peptide 1, Measured in pmol/literGLP-2Time Frame: 120 minGlucagon-like peptide 2, Measured in pmol/literInsulinTime Frame: 120 minMeasured in pmol/literGIPTime Frame: 120 minGlucose dependent insulinotropic hormone, Measured in pmol/literOXMTime Frame: 120 minOxytomodulin, Measured in pmol/literAmino acidsTime Frame: 120 minMeasured in pmol/literCCKTime Frame: 120 minCholecystokinin, Measured in pmol/literGastrinTime Frame: 120 minMeasured in pmol/literFGF-19Time Frame: 120 minFibroblast Growth factor 19, Measured in ng/mLFGF-21Time Frame: 120 minFibroblast Growth factor 21, Measured in ng/mLBile acidsTime Frame: 120 minMeasured in nmol/mlNorepinephrineTime Frame: 120 minMeasured in pmol/literGHTime Frame: 120 minGrowth hormone, Measured in nmol/mlP1NPTime Frame: 120 minProcollagen type I N-terminal propeptide (Bonemarker), Measured in nmol/mlCTXTime Frame: 120 minC-terminal telopeptide (Bonemarker), Measured in nmol/mlGallbladder ultrasoundTime Frame: 120 minMeasuring of gallbladder size in respons to GLP-2Participating in This Clinical TrialInclusion CriteriaCaucasian ethnicityBody mass index (BMI): 18.5-27 kg/m2Glycated haemoglobin (HbA1c) &lt; 42 mmol/molNormal haemoglobin (8.3-10.5 mmol/l)Informed and oral and written consentExclusion CriteriaPrediabetes, type 1 diabetes or type 2 diabetes or first-degree relatives with type 1 or type 2 diabetesNephropathy (eGFR &lt; 60 and/or albuminuria)Known liver disease and/or alanine transaminase (ALAT) or aspartate transaminase (ASAT) &gt; 2 × upper normal limitBilirubin &gt; 25 μmol/lKnown intestinal disease or previous surgery of the intestinesActive or recent malignant diseaseTreatment with medicine that cannot be paused for 12 hoursAny condition considered incompatible with participation by the investigatorsGender Eligibility: MaleMinimum Age: 18 YearsMaximum Age: 40 YearsAre Healthy Volunteers Accepted: Accepts Healthy VolunteersInvestigator DetailsLead SponsorUniversity Hospital, Gentofte, CopenhagenProvider of Information About this Clinical StudyPrincipal Investigator: Filip Krag Knop, Prof. MD – University Hospital, Gentofte, CopenhagenOverall Official(s)Filip Krag Knop, MD, PhD, Study Director, Center for Clinical Metabolic ResearchInformation SourceID Number: H-18046965NCT Identifier: NCT03954873NCT03954873, May 17, 2019Clinical trials entries are delivered from the US National Institutes of Health and are not reviewed separately by this site. Please see the identifier information above for retrieving further details from the government database. https://trialbulletin.com/lib/entry/ct-03954873",https://t.co/xBAIgxSBPI,others
Minerva,"Enige tijd geleden bespraken we in Minerva het effect van enerzijds de SGLT2-inhibitoren empagliflozine en canagliflozine (1-4) en anderzijds de GLP-1-analoog liraglutide (5,6) op cardiovasculaire uitkomsten. Voor empagliflozine en canagliflozine kon men versus placebo een statistisch significante daling van een samengestelde cardiovasculaire uitkomstmaat bestaande uit cardiovasculaire mortaliteit, niet-fataal myocardinfarct en niet-fataal CVA aantonen bij patiënten met type 2-diabetes en hoog cardiovasculair risico (1-4). In verband met liraglutide konden we ondanks een gunstig effect versus placebo op eenzelfde samengestelde cardiovasculaire uitkomstmaat niets definitief besluiten over de cardioprotectieve effectiviteit wegens een door het protocol geïnduceerd onevenwicht tussen de interventie- en de placebogroep. Zo bleek immers dat de placebogroep significant meer hypoglykemiërende middelen gebruikte en er zich meer ernstige gevallen van hypoglykemie voordeden (5,6). In dezelfde 'LEADER'-studie (6) onderzocht men ook het effect van liraglutide op een vooraf gedefinieerd, secundair, samengesteld renaal eindpunt (optreden van macroalbuminurie, verdubbeling van serumcreatinine, terminaal nierlijden, sterfte ten gevolge van nierlijden) bij de 9 340 geïncludeerde type 2-diabetespatiënten met een hoog cardiovasculair risico (≥50 jaar en voorgeschiedenis van een cardiovasculaire aandoening of ≥60 jaar en minstens 1 cardiovasculaire risicofactor) (7). Na een mediane follow-up van 3,84 jaar kwam het renaal eindpunt minder voor in de liraglutide- versus de placebogroep (HR 0,78 met 95% BI van 0,67 tot 0,92). Alhoewel deze studie niet voldoende power had voor individuele renale eindpunten, suggereren de resultaten wel dat de winst vooral afhangt van een verminderd optreden van macroalbuminurie. Een daling in het optreden van macroalbuminurie zonder onmiddellijk effect op andere renale eindpunten zagen we ook in de UKPDS- (8), de ACCORD- (9) en de ADVANCE- (10) studie. In deze studies werd een daling van macroalbuminurie in verband gebracht met een daling van HbA1c. Tot op heden hebben alleen de SGLT2 inhibitoren een statistisch significant effect op vermindering van achteruitgang van de nierfunctie en optreden van terminaal nierlijden aangetoond (3,4,11,12). In een pragmatische RCT randomiseerde men 14 752 patiënten met type 2-diabetes (mediane diabetesduur 12 jaar met IQR van 7 tot 18 jaar en mediane HbA1c 8,0% met IQR van 7,3 tot 8,9%), waarvan 73% met een cardiovasculaire voorgeschiedenis (16% met hartfalen), in een groep die wekelijks subcutaan 2 mg exenatide kreeg (n=7 356 patiënten) en een groep die wekelijks placebo kreeg (n=7 396 patiënten) (13). Na een (mediane) opvolgduur van 3,2 jaar (met IQR van 2,2 tot 4,4 jaar) kon men tussen beide groepen geen statistisch significante verschillen vaststellen in een samengesteld cardiovasculair eindpunt (bestaande uit cardiovasculaire sterfte, niet-fataal myocardinfarct en niet-fataal CVA) (HR 0,91 met 95% BI van 0,83 tot 1,00). Er was echter wel een statistisch significant verschil in de secundaire uitkomstmaat globale mortaliteit (HR 0,86 met 95% BI van 0,77 tot 0,96). Ook de ELIXA-studie bij 6 068 patiënten met type 2-diabetes en voorgeschiedenis van myocardinfarct of hospitalisatie wegens instabiele angor kon na mediaan 25 maanden geen statistisch significante winst in cardiovasculaire morbiditeit en mortaliteit met lixisenatide versus placebo aantonen (14). Net zoals in de LEADER-studie kon met semaglutide dan weer wél een statistisch significant cardiovasculair voordeel ten opzichte van placebo aangetoond worden bij 2 735 patiënten met hoog cardiovasculair risico, chronisch hartfalen of ernstige chronische nierziekte (15). Deze molecule is echter niet beschikbaar in België. Momenteel is het dus niet duidelijk in hoeverre het cardiovasculair effect van GLP-1-analogen een klasse-effect is, of het effect 'absoluut' (inherent aan de molecule) of eerder 'relatief' (minder cardiovasculaire gebeurtenissen ten opzichte van de minder veilige hypoglykemiërende sulfamiden) is en wat de onderliggende mechanismen zijn. De evidentie over cardiorenale bescherming met SGLT2-inhibitoren daarentegen lijkt meer consistent te zijn. Maar ook hier is verder onderzoek naar de mechanismen en eventueel betere aflijning van de doelgroepen noodzakelijk. BesluitHet effect van GLP-1-analogen op 'harde' eindpunten zoals cardiovasculaire gebeurtenissen en progressief nierfalen blijft momenteel nog onduidelijk. Met liraglutide kon geen effect op een daling van de nierfunctie, noch op het optreden van terminaal nierlijden versus placebo aangetoond worden in een studie met een samengesteld cardiovasculair eindpunt als primaire uitkomstmaat. Een statistisch significante winst op cardiovasculair vlak kon men niet aantonen met exenatide versus placebo bij patiënten met type 2-diabetes en een belangrijke cardiovasculaire voorgeschiedenis. Voor de praktijkDe richtlijn voor goede medische praktijkvoering van Domus Medica over type 2-diabetes raadt aan om te starten met metformine wanneer leefstijlaanpassingen na een periode van 3 maanden niet helpen om de HbA1c-streefwaarde te bereiken (GRADE 1A) (16). Wanneer een monotherapie met metformine na 3 maanden niet volstaat om de HbA1c-streefwaarde te bereiken, stelt men voor om een tweede oraal antidiabeticum (sulfonylureum/glinide, DPP-4-inhibitor, glitazone of SGLT2-inhibitor) toe te voegen (GRADE 1C). De European Association for the Study of Diabetes (EASD) en the American Diabetes Association (ADA) formuleerden onlangs nieuwe aanbevelingen met GLP-1-analogen en SGLT2-inhibitoren als preferentiële tweede stap in de behandeling van type 2-diabetes bij patiënten met cardiovasculaire co-morbiditeit (na metformine als eerste keuze) (17). Bij diabetici die daarnaast ook lijden aan ernstig chronisch nierlijden of hartfalen, is een SGLT2-inhibitor de eerste keuze. Deze aanbevelingen van ADA/EASD lijken op basis van de huidige evidentie correct te zijn. In tegenstelling tot sulfonylureum en DPP-4-inhibitoren is voor SGLT2-inhibitoren en voor sommige GLP-1-analogen (wel voor liraglutide maar niet voor exenatide en lixisenatide) immers wel een cardiovasculair protectief effect aangetoond. Referenties Wens J. Empagliflozine: ook effect op cardiovasculaire morbiditeit en mortaliteit bij patiënten met type 2-diabetes? Minerva 2016;15(4):98-101. Zinman B, Wanner C, Lachin JM, et al; EMPA-REG OUTCOME Investigators. Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes. N Engl J Med 2015;373:2117-28. DOI: 10.1056/NEJMoa1504720 Richard T. Canagliflozine: welk effect op cardiovasculaire en renale gebeurtenissen bij patiënten met type 2-diabetes? Minerva bondig 15/09/2018. Neal B, Perkovic V, Mahaffey KW, et al; CANVAS Program Collaborative Group. Canagliflozin and cardiovascular and renal events in type 2 diabetes. NEJM 2017;377:644-57. DOI: 10.1056/NEJMoa1611925 Vanhaeverbeek M. Liraglutide voor de behandeling van type 2-diabetes: cardiovasculaire risico's? Minerva bondig 15/02/2017. Marso SP, Daniels GH, Brown-Frandsen K, et al. Liraglutide and cardiovascular outcomes in type 2 diabetes. N Engl J Med 2016;375:311-22. DOI: 10.1056/NEJMoa1603827 Mann JFE, Ørsted DD, Brown-Frandsen K, et al. Liraglutide and renal outcomes in type 2 diabetes. N Engl J Med 2017;377:839-48. DOI: 10.1056/NEJMoa1616011 UK Prospective Diabetes Study (UKPDS) Group. Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). Lancet 1998;352, 854-65. DOI: 10.1016/S0140-6736(98)07037-8 Gerstein HC, Miller ME, Byington RP, et al. Effects of intensive glucose lowering in type 2 diabetes. N Engl J Med 2008;358:2545–59. DOI: 10.1056/NEJMoa0802743 Zoungas S, Woodward MLi Q, et al; ADVANCE Collaborative Group. Impact of age, age at diagnosis and duration of diabetes on the risk of macrovascular and microvascular complications and death in type 2 diabetes. Diabetologia 2014;57:2465–74. DOI: 10.1007/s00125-014-3369-7 Wens J. Voorkomt empagliflozine nierziekte bij type 2-diabetespatiënten? Minerva bondig 15/12/2016. Wanner C, Inzucchi SE, Lachin JM, et al. Progression of kidney disease in type 2 diabetes. N Engl J Med 2016;375:323-34. DOI: 10.1056/NEJMoa1515920 Holman RR, Bethel MA, Mentz RJ, et al. Effects of once-weekly exenatide on cardiovascular outcomes in type 2 diabetes. N Engl J Med 2017;377:1228-39. DOI: 10.1056/NEJMoa1612917 Pfeffer MA, Claggert B, Diaz R, et al. Lixisenatide in patients with type 2 diabetes and acute coronary syndrome. N Engl J Med 2015;373:2247-57. DOI: 10.1056/NEJMoa1509225 Marso SP, Bain SC, Consoli A, et al ; SUSTAIN-6 Investigators. Semaglutide and cardiovascular outcomes in patients with type 2 diabetes. N Engl J Med 2016;375:1834-44. DOI: 10.1056/NEJMoa1607141 Koeck P. Bastiaens H, Benhalima K, et al. Diabetes mellitus type 2. Richtlijn voor goede medische praktijkvoering. Domus Medica 2015. New EASD-ADA consensus guidelines on managing hyperglycaemia in type 2 diabetes launched at EASD meeting. New recommendations include specific drug classes for some patients and enhancing medication adherence. URL: https://diabetologia-journal.org/2018/10/05/new-easd-ada-consensus-guidelines-on-managing-hyperglycaemia-in-type-2-diabetes-launched-at-easd-meeting-new-recommendations-include-specific-drug-classes-for-some-patients-and-enhancing-medication-a/",https://t.co/gZ14N3k2Dv,others
Substrate-selective inhibitors that reprogram the activity of insulin-degrading enzyme,"1.Mirsky, I. A. &amp; Broh-Kahn, R. H. The inactivation of insulin by tissue extracts; the distribution and properties of insulin inactivating extracts. Arch. Biochem. 20, 1–9 (1949).2.Duckworth, W. C. &amp; Kitabchi, A. E. Insulin and glucagon degradation by the same enzyme. Diabetes 23, 536–543 (1974).3.Roglic, G. &amp; World Health Organization. Global Report on Diabetes (World Health Organization, 2016).4.Costes, S. &amp; Butler, P. C. Insulin-degrading enzyme inhibition, a novel therapy for type 2 diabetes? Cell. Metab. 20, 201–203 (2014).5.Tang, W. J. Targeting insulin-degrading enzyme to treat type 2 diabetes mellitus. Trends Endocrinol. Metab. 27, 24–34 (2016).6.Duckworth, W. C., Bennett, R. G. &amp; Hamel, F. G. Insulin degradation: progress and potential. Endocr. Rev. 19, 608–624 (1998).7.Abdul-Hay, S. O. et al. Deletion of insulin-degrading enzyme elicits antipodal, age-dependent effects on glucose and insulin tolerance. PLoS One 6, e20818 (2011).8.Farris, W. et al. Insulin-degrading enzyme regulates the levels of insulin, amyloid beta-protein, and the beta-amyloid precursor protein intracellular domain in vivo. Proc. Natl Acad. Sci. USA 100, 4162–4167 (2003).9.Villa-Perez, P. et al. Liver-specific ablation of insulin-degrading enzyme causes hepatic insulin resistance and glucose intolerance, without affecting insulin clearance in mice. Metab. Clin. Exp. 88, 1–11 (2018).10.Steneberg, P. et al. The type 2 diabetes-associated gene ide is required for insulin secretion and suppression of alpha-synuclein levels in beta-cells. Diabetes 62, 2004–2014 (2013).11.Maianti, J. P. et al. Anti-diabetic activity of insulin-degrading enzyme inhibitors mediated by multiple hormones. Nature 511, 94–98 (2014).12.Durham, T. B. et al. Dual exosite-binding inhibitors of insulin-degrading enzyme challenge its role as the primary mediator of insulin clearance in vivo. J. Biol. Chem. 290, 20044–20059 (2015).13.Ahren, B. Avoiding hypoglycemia: a key to success for glucose-lowering therapy in type 2 diabetes. Vasc. Health Risk Manag. 9, 155–163 (2013).14.Bennett, R. G., Duckworth, W. C. &amp; Hamel, F. G. Degradation of amylin by insulin-degrading enzyme. J. Biol. Chem. 275, 36621–36625 (2000).15.Malito, E., Hulse, R. E. &amp; Tang, W. J. Amyloid beta-degrading cryptidases: insulin degrading enzyme, presequence peptidase, and neprilysin. Cell. Mol. Life Sci. 65, 2574–2585 (2008).16.Unger, R. H. &amp; Cherrington, A. D. Glucagonocentric restructuring of diabetes: a pathophysiologic and therapeutic makeover. J. Clin. Inv. 122, 4–12 (2012).17.Drag, M. &amp; Salvesen, G. S. Emerging principles in protease-based drug discovery. Nat. Rev. Drug Discov. 9, 690–701 (2010).18.Berg, D. T., Wiley, M. R. &amp; Grinnell, B. W. Enhanced protein C activation and inhibition of fibrinogen cleavage by a thrombin modulator. Science 273, 1389–1391 (1996).19.Xu, X., Chen, Z., Wang, Y., Bonewald, L. &amp; Steffensen, B. Inhibition of MMP-2 gelatinolysis by targeting exodomain-substrate interactions. Biochem. J. 406, 147–155 (2007).20.Knapinska, A. M. et al. SAR studies of exosite-binding substrate-selective inhibitors of A disintegrin and metalloprotease 17 (ADAM17) and application as selective in vitro probes. J. Med. Chem. 58, 5808–5824 (2015).21.Madoux, F. et al. Discovery of an enzyme and substrate selective inhibitor of ADAM10 using an exosite-binding glycosylated substrate. Sci. Rep. 6, 11 (2016).22.Panwar, P. et al. Tanshinones that selectively block the collagenase activity of cathepsin K provide a novel class of ectosteric antiresorptive agents for bone. Br. J. Pharmacol. 175, 902–923 (2018).23.Leissring, M. A. et al. Designed inhibitors of insulin-degrading enzyme regulate the catabolism and activity of insulin. PLoS ONE 5, e10504 (2010).24.Deprez-Poulain, R. et al. Catalytic site inhibition of insulin-degrading enzyme by a small molecule induces glucose intolerance in mice. Nat. Comm. 6, 8250 (2015).25.Hendriks, B. S., Seidl, K. M. &amp; Chabot, J. R. Two additive mechanisms impair the differentiation of 'substrate-selective' p38 inhibitors from classical p38 inhibitors in vitro. BMC Syst. Biol. 4, 23 (2010).26.Abdul-Hay, S. O. et al. Optimization of peptide hydroxamate inhibitors of insulin-degrading enzyme reveals marked substrate-selectivity. J. Med. Chem. 56, 2246–2255 (2013).27.Charton, J. et al. Imidazole-derived 2-[N-carbamoylmethyl-alkylamino]acetic acids, substrate-dependent modulators of insulin-degrading enzyme in amyloid-beta hydrolysis. Eur. J. Med. Chem. 79, 184–193 (2014).28.Abdul-Hay, S. O. et al. Selective targeting of extracellular insulin-degrading enzyme by quasi-irreversible thiol-modifying inhibitors. ACS Chem. Biol. 10, 2716–2724 (2015).29.Charton, J. et al. Structure-activity relationships of imidazole-derived 2-[N-carbamoylmethyl-alkylamino]acetic acids, dual binders of human insulin-degrading enzyme. Eur. J. Med. Chem. 90, 547–567 (2015).30.Busschots, K. et al. Substrate-selective inhibition of protein kinase PDK1 by small compounds that bind to the PIF-pocket allosteric docking site. Chem. Biol. 19, 1152–1163 (2012).31.Rettenmaier, T. J. et al. A small-molecule mimic of a peptide docking motif inhibits the protein kinase PDK1. Proc. Natl Acad. Sci. USA 111, 18590–18595 (2014).32.Shah, N. G. et al. Novel noncatalytic substrate-selective p38alpha-specific MAPK inhibitors with endothelial-stabilizing and anti-Inflammatory activity. J. Immunol. 198, 3296–3306 (2017).33.Hall, M. D. et al. Fluorescence polarization assays in high-throughput screening and drug discovery: a review. Methods Appl. Fluoresc. 4, 022001 (2016).34.Lowe, J. T. et al. Synthesis and profiling of a diverse collection of azetidine-based scaffolds for the development of CNS-focused lead-like libraries. J. Org. Chem. 77, 7187–7211 (2012).35.Malito, E. et al. Molecular bases for the recognition of short peptide substrates and cysteine-directed modifications of human insulin-degrading enzyme. Biochemistry 47, 12822–12834 (2008).36.Sebaugh, J. L. Guidelines for accurate EC50/IC50 estimation. Pharm. Stat. 10, 128–134 (2011).37.Degorce, F. et al. HTRF: A technology tailored for drug discovery—a review of theoretical aspects and recent applications. Curr. Chem. Genomics 3, 22–32 (2009).38.Leung, C. S., Leung, S. S., Tirado-Rives, J. &amp; Jorgensen, W. L. Methyl effects on protein-ligand binding. J. Med. Chem. 55, 4489–4500 (2012).39.Shroyer, L. A. &amp; Varandani, P. T. Purification and characterization of a rat liver cytosol neutral thiol peptidase that degrades glucagon, insulin, and isolated insulin A and B chains. Arch. Biochem. Biophys. 236, 205–219 (1985).40.Shen, Y., Joachimiak, A., Rosner, M. R. &amp; Tang, W. J. Structures of human insulin-degrading enzyme reveal a new substrate recognition mechanism. Nature 443, 870–874 (2006).41.Leissring, M. A. &amp; Selkoe, D. J. Structural biology: enzyme target to latch on to. Nature 443, 761–762 (2006).42.McCord, L. A. et al. Conformational states and recognition of amyloidogenic peptides of human insulin-degrading enzyme. Proc. Natl Acad. Sci. USA 110, 13827–13832 (2013).43.Song, E. S., Juliano, M. A., Juliano, L. &amp; Hersh, L. B. Substrate activation of insulin-degrading enzyme (insulysin). A potential target for drug development. J. Biol. Chem. 278, 49789–49794 (2003).44.Im, H. et al. Structure of substrate-free human insulin-degrading enzyme (IDE) and biophysical analysis of ATP-induced conformational switch of IDE. J. Biol. Chem. 282, 25453–25463 (2007).45.Song, E. S., Rodgers, D. W. &amp; Hersh, L. B. A monomeric variant of insulin degrading enzyme (IDE) loses its regulatory properties. PLoS One 5, e9719 (2010).46.Duggan, K. C. et al. (R)-Profens are substrate-selective inhibitors of endocannabinoid oxygenation by COX-2. Nat. Chem. Biol. 7, 803–809 (2011).47.Rose, K. et al. Insulin proteinase liberates from glucagon a fragment known to have enhanced activity against Ca2+ + Mg2+-dependent ATPase. Biochem. J. 256, 847–851 (1988).48.Vandenbroucke, R. E. &amp; Libert, C. Is there new hope for therapeutic matrix metalloproteinase inhibition? Nat. Rev. Drug Discov. 13, 904–927 (2014).49.McMurray, J. J. Neprilysin inhibition to treat heart failure: a tale of science, serendipity, and second chances. Eur. J. Heart Fail. 17, 242–247 (2015).50.Zeke, A. et al. Systematic discovery of linear binding motifs targeting an ancient protein interaction surface on MAP kinases. Mol. Syst. Biol. 11, 837 (2015).51.Geu-Flores, F., Nour-Eldin, H. H., Nielsen, M. T. &amp; Halkier, B. A. USER fusion: a rapid and efficient method for simultaneous fusion and cloning of multiple PCR products. Nucleic Acid. Res. 35, e55 (2007).52.Vonrhein, C. et al. Data processing and analysis with the autoPROC toolbox. Acta Crystallogr. D 67, 293–302 (2011).53.McCoy, A. J. et al. Phaser crystallographic software. J. Appl. Crystallogr. 40, 658–674 (2007).54.Emsley, P. &amp; Cowtan, K. Coot: model-building tools for molecular graphics. Acta Crystallogr. D 60, 2126–2132 (2004).55.Adams, P. D. et al. PHENIX: a comprehensive Python-based system for macromolecular structure solution. Acta Crystallogr. D 66, 213–221 (2010).56.APEX2 v.2014.11-0 (Bruker AXS, Madison, WI, USA, 2014).57.Krause, L., Herbst-Irmer, R., Sheldrick, G. M. &amp; Stalke, D. Comparison of silver and molybdenum microfocus X-ray sources for single-crystal structure determination. J. Appl. Crystallogr. 48, 3–10 (2015).58.Sheldrick, G. M. SHELXT—integrated space-group and crystal-structure determination. Acta Crystallogr. A 71, 3–8 (2015).59.Sheldrick, G. M. Crystal structure refinement with SHELXL. Acta Crystallogr. C 71, 3–8 (2015).60.Dolomanov, O. V., Bourhis, L. J., Gildea, R. J., Howard, J. A. K. &amp; Puschmann, H. OLEX2: a complete structure solution, refinement and analysis program. J. App. Crystallogr. 42, 339–341 (2009).",https://t.co/ucRn2hiOpS,others
Minerva,"Dans le schéma de titration du traitement hypoglycémiant du diabète sucré de type 2, les analogues du glucagon-like peptide-1 (GLP-1), également appelés incrétinomimétiques, occupent la même place que l'insuline basale (1). Ils sont ajoutés aux antidiabétiques oraux lorsque ces derniers ne suffisent plus pour atteindre la valeur cible de la glycémie (1). Par comparaison avec un placebo, il a été montré qu'ils n'entraînent pas d'épisodes d'hypoglycémie et qu'ils s'accompagnent d'une perte de poids (2,3). Une comparaison directe entre les analogues du GLP-1 et l'insuline basale peut donc avoir son utilité pour la prise de décision clinique. Une synthèse méthodique avec méta-analyse a inclus 11 études comparatives examinant l'effet de l'ajout d'analogues du GLP-1 par voie sous-cutanée, versus insuline basale, comme traitement ajouté aux antidiabétiques oraux sur l'HbA1c et sur le poids corporel (4). Les résultats suivants ont été observés : tous les analogues du GLP-1 ont entraîné, versus insuline glargine, une perte de poids : -1,98 kg (avec IC à 95% de -2,32 à -1,64) avec le dulaglutide à raison de 0,75 mg une fois par semaine, -4,31 kg (avec IC à 95% de -4,71 à -3,90) avec l'exénatide à raison de 10 µg deux fois par jour ; l'effet sur l'HbA1c était moins uniforme ; des diminutions statistiquement significatives de l'HbA1c ont été observées : de -0,31% (avec IC à 95% de -0,42 à -0,19) avec l'exénatide à raison de 2 mg une fois par semaine versus insuline glargine, de -0,42% (avec IC à 95% de -0,54 à -0,20) avec l'exénatide à raison de 2 mg une fois par semaine versus insuline détémir, de -0,39% (avec IC à 95% de -0,49 à -0,29) avec le dulaglutide à raison de 0,75 mg une fois par semaine versus insuline glargine, de -0,58% (avec IC à 95% de -0,72 à -0,44) avec le dulaglutide à raison de 1,5 mg une fois par semaine versus insuline glargine ; aucune différence statistiquement significative n'a été mise en évidence au niveau de l'HbA1c avec l'ajout par voie sous-cutanée de liraglutide à raison de 1,8 mg une fois par jour, ou d'exénatide à raison de 10 µg deux fois par jour, versus insuline glargine. Une autre synthèse méthodique avec méta-analyse (5) comparant les analogues du GLP-1 avec l'insuline basale est arrivée à des résultats comparables : aucune diminution de l'HbA1c avec les analogues du GLP-1 de courte durée d'action versus insuline basale ; diminution de l'HbA1c avec les analogues du GLP-1 de longue durée d'action versus insuline basale : -0,17% avec IC à 95% de -0,22% à -0,12%.Par comparaison avec un schéma basal-bolus, aucune différence statistiquement significative avec les analogues du GLP-1 n'a pu être montrée. Il est également apparu que l'insuline basale versus analogues du GLP-1 avait un effet plus puissant sur la glycémie à jeun : -1,78 mmol/l avec IC à 95% de -1,83 à -1,73. Par ailleurs, d'autres avantages avec les analogues du GLP-1 versus insuline basale ont pu être observés : diminution du poids (-3,71 kg avec IC à 95% de -3,88 à -3,54) ; réduction absolue du risque de 15,6% (avec IC à 95% de 13,1% à 18,1%) des épisodes hypoglycémiques (p &lt; 0,0001) ; diminution absolue de 2,8 mmHg (avec IC à 95% de -3,6 à -2,0) de la pression artérielle systolique ; diminution de 0,23 mmol/l (avec IC à 95% de -0,31 à -0,16) du taux de triglycérides ; et diminution de 0,13 mmol/l (avec IC à 95% de -0,18 à -0,09) du taux de LDL-cholestérol, sans différence quant au taux de HDL-cholestérol. On ne sait pas encore si ces améliorations de critères de jugement intermédiaires entraîneront aussi une diminution du nombre d'événements cardiovasculaires. ConclusionDeux synthèses méthodiques avec méta-analyse permettent de conclure que les analogues du GLP-1 représentent une alternative sûre à l'insuline basale dans le schéma de titration du traitement hypoglycémiant chez les patients ayant un diabète de type 2. Les préparations de longue durée d'action se sont avérées plus efficaces que celles de courte durée d'action. Pour la pratique Lorsque l'association d'antidiabétiques oraux à la dose maximale tolérée est insuffisante pour atteindre une valeur cible individuelle pour l'HbA1c, le GPC de Domus Medica (1) recommande d'y ajouter de l'insuline ou un analogue du GLP-1 (GRADE 1B). Lors de l'instauration d'une insulinothérapie, une insuline basale (NPH) au coucher sera préférée (GRADE 1A). En cas d'épisodes d'hypoglycémie, passer à des analogues de l'insuline à action prolongée (insuline glargine) est un choix cohérent (GRADE 1C). Un analogue du GLP-1 est à préférer chez les patients obèses et chez les patients chez qui l'hypoglycémie représente un danger particulier (GRADE 1C). Il est important de prévoir une éducation spécifique et un contrôle personnel au début du traitement par agoniste du GLP-1 ou par insuline (GRADE 1A). Deux synthèses méthodiques avec méta-analyse confirment que l'insuline basale et les analogues du GLP-1 ont une efficacité comparable. Une diminution du poids a été observée avec les analogues du GLP-1 versus insuline basale. Références Insulinothérapie dans le diabète de type 2. Duodecim Medical Publications. Dernière mise à jour: 6/08/2017. Dernière révision contextuelle: 11/04/2019. Ruige J. Exénatide en ajout à un antidiabétique oral ? MinervaF 2008;7(3):38-9. Zinman B, Hoogwerf BJ, Duran Garcia SD, et al. The effect of adding exenatide to a thiazolidinedione in suboptimally controlled type 2 diabetes. Ann Intern Med 2007;146:477-85. DOI: 10.7326/0003-4819-146-7-200704030-00003 Singh S, Wright EE, Kwan AY, et al. Glucagon-like peptide-1 receptor agonists compared with basal insulins for the treatment of type 2 diabetes mellitus: a systematic review and meta-analysis. Diabetes Obes Metab 2017;19:228-38. DOI: 10.1111/dom.12805 Abd El Aziz MS, Kahle M, Meier JJ, Nauck MA. A meta-analysis comparing clinical effects of short- or long-acting GLP-1 receptor agonists versus insulin treatment from head-to-head studies in type 2 diabetic patients. Diabetes Obes Metab 2017;19:216-27. DOI: 10.1111/dom.12804",https://t.co/ZQkSeKQZEJ,others
Incorporating Glucagon-Like Peptide-1 Receptor Agonists in the Individualized Management of Patients with Type 2 Diabetes,"Incorporating Glucagon-Like Peptide-1 Receptor Agonists in the Individualized Management of Patients with Type 2 Diabetes Release Date: March 29, 2019Last Reviewed: March 23, 2019Expiration Date: March 29, 2020Time to Complete Activity: 1.0 hour Faculty Vivian Fonseca, MD Professor of Medicine and PharmacologyTullis-Tulane Alumni Chair in DiabetesChief, Section of EndocrinologyTulane University Health Sciences CenterNew Orleans, LA Steering Committee Jeff Unger, MD, FAAFP, FACEAssistant Clinical Professor of Family MedicineUC Riverside School of MedicineDirector, Unger Concierge Primary Care Medical GroupRancho Cucamonga, CA Vivian Fonseca, MD Professor of Medicine and PharmacologyTullis-Tulane Alumni Chair in DiabetesChief, Section of EndocrinologyTulane University Health Sciences CenterNew Orleans, LAThis activity is provided by Paradigm Medical Communications, LLC. Target AudienceThis activity has been designed to address the educational needs of family practice and other primary care clinicians involved in the management of patients with type 2 diabetes (T2D). Statement of Need With the advent of glucagon-like peptide-1 receptor agonists (GLP-1 RAs), we have entered a new era of T2D treatment. These antidiabetic agents lower plasma glucose levels, and recent data show that some of them decrease the risk of macrovascular events. Guidelines have evolved that direct clinicians to use GLP-RAs earlier to maximize their benefit. Family practice clinicians, at the forefront of primary care, need to be up to date on the pharmacology of newer GLP-1 RAs, how to distinguish among available and emerging agents within the class, which patients will most benefit from GLP-1 RAs, and how to best incorporate them into patient management plans. Learning ObjectivesUpon proper completion of this activity, participants should be better able to:Describe the mechanisms of action by which current and emerging GLP-1 RAs exert beneficial glycemic and extraglycemic effects on patients with T2D.Match current and emerging GLP-1 RAs with appropriate patients based on unique agent characteristics (eg, dosing strategies, efficacy, and safety), current guideline recommendations, patient clinical characteristics, and patient preferences.Describe clinician–patient communication strategies for promoting patient adherence to T2D treatment plans that include injectable therapies.Physician Accreditation StatementParadigm Medical Communications, LLC is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.Physician Credit Designation StatementParadigm Medical Communications, LLC designates this enduring material for a maximum of 1.0 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.PA Continuing EducationPAs may claim a maximum of 1.0 Category 1 credit for completing this activity. NCCPA accepts AMA PRA Category 1 Credit™ from organizations accredited by ACCME or a recognized state medical society. Nurse Practitioner Continuing EducationThe American Academy of Nurse Practitioners Certification Program (AANPCP) accepts certificates of participation for educational activities certified for AMA PRA Category 1 Credit™ from organizations accredited by the ACCME. Individuals are responsible for checking with the AANPCP for further guidelines.AAFP CreditThis Enduring Material activity, Incorporating Glucagon-Like Peptide-1 Receptor Agonists in the Individualized Management of Patients with Type 2 Diabetes, has been reviewed and is acceptable for up to 1.00 Prescribed credit(s) by the American Academy of Family Physicians. AAFP certification begins 03/29/2019. Term of approval is for one year from this date. Physicians should claim only the credit commensurate with the extent of their participation in the activity.Disclosure of Commercial SupportThis activity is supported by an educational grant from Lilly. Instructions for ParticipationTo receive a CME certificate of participation, you should:Follow instructions to register or log in with your professional information and complete the pretestView the online activity in its entiretyComplete and submit the online posttest and evaluationA certificate of participation will be available for download/printing immediately following your successful completion of the posttest and evaluation.For questions regarding CME credit, contact the Paradigm CME Department at (845) 398-5949. There is no fee required for participation in this activity. Hardware/Software RequirementsThis certified CME activity is designed using HTML5 audio. Supported Browsers:For desktops (Windows/Mac)Internet Explorer 9 or higher, Firefox 28 or higher, Safari 5.1 or higher, Google Chrome 31 or higher, Opera 21 or higher For Tablets (iPad/Android/Surface)iOS Safari 4 or higher, Android 2.3 or higher, IE Mobile 10 or higher DisclosuresIn accordance with Accreditation Council for Continuing Medical Education requirements on disclosure, faculty and contributors are asked to disclose any relationships with commercial interests associated with the area of medicine featured in the activity. These relationships are described below. Faculty/Steering CommitteeJeff Unger, MD, FAAFP, FACEConsulting Fees: Abbott Laboratories; Janssen Pharmaceuticals, Inc; Novo Nordisk, IncSpeaker Bureau: Janssen Pharmaceuticals, Inc; Novo Nordisk, IncContracted Research: Janssen Pharmaceuticals, Inc; Novo Nordisk, Inc; Mylan NV; sanofi-aventis U.S. LLCOwnership Interest: Novo Nordisk, IncRoyalty: Lippincott Williams &amp; Wilkins Vivian Fonseca, MD Contracted Research: Bayer HealthCare; Boehringer Ingelheim Pharmaceuticals, IncConsulting Fees: Asahi Kasei Pharma Corporation; AstraZeneca; Eli Lilly and Company; Intarcia Therapeutics, Inc; Novo Nordisk Inc; sanofi-aventis U.S. LLC; Takeda Pharmaceutical Company Ltd Paradigm Medical Communications, LLC staff members have no financial relationships to disclose.Peer reviewer, Carol Levy, MD, CDE, has the following relationships to disclose:Retained Consultant: sanofi-aventis U.S. LLCResolution of Conflict of InterestParadigm Medical Communications, LLC has implemented a system to resolve conflicts of interest for each CME activity to help ensure content objectivity, independence, fair balance, and that the content is aligned with the interest of the public. Conflicts, if any, are resolved through one or more processes. All CME content in this activity was independently reviewed to ensure that it is free of commercial bias, scientifically rigorous, aligned with the public interest, and compliant with all regulatory guidance and the ACCME's Standards for Commercial Support of Continuing Medical Education.Disclosure of Unlabeled UseThis educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. DisclaimerThis CME activity represents the views and opinions of the individual faculty, and does not constitute the opinion or endorsement of, or promotion by, Paradigm Medical Communications, LLC. Reasonable efforts have been taken to present educational subject matter in a balanced, unbiased fashion, and in compliance with regulatory requirements. However, each activity participant must always use his or her own personal and professional judgment when considering further application of this information, particularly as it may relate to patient diagnostic or treatment decisions including, without limitation, FDA-approved uses and any off-label uses.If included, signed statements of informed consent granting permission for publication have been obtained for all photographs and videos in which an individual can be identified. As an ACCME-accredited provider, Paradigm Medical Communications, LLC activities must include a balanced view of therapeutic options. Use of generic names contributes to this impartiality. The use of trade names should not be viewed as an endorsement of specific products by Paradigm Medical Communications, LLC. Terms of Use and Privacy PolicyDisclaimerThe materials provided for this activity are for informational purposes only, and should not be used for diagnosis or treatment of a health problem without consulting a licensed medical professional. Any views or opinions presented are solely those of the faculty, and do not necessarily represent those of Paradigm Medical Communications, LLC. References to any entity, product, service, or source of information on this website should not be considered an endorsement, either direct or implied, by Paradigm. Paradigm accepts no liability for the content referenced in this activity. Privacy policyParadigm Medical Communications, LLC is committed to protecting the privacy of those who participate in the activities (herein referred to as ""website"") located at www.paradigmmc.com. The information below describes the security of the website for safeguarding personal information and the rationale for collection and use of personal information. Security/safeguarding personal informationThis website has physical and procedural safeguards in place to prevent unauthorized access to personal information used to access this website. Collection and use of your personal informationThe submission of certain personally identifiable information is necessary to award and track the credits participants may earn after completing the program. Required items include first name, last name, degree, and email address. These items are necessary. Participants are also required to complete an evaluation of the CME activity. All evaluative information submitted is collected and retained, and used by Paradigm to continuously improve the learning experience. Paradigm Medical Communications, LLC does not transfer, sell, or share personal information with outside parties. Paradigm will not otherwise disclose personal information unless required to in a legal process. Paradigm staff members review individual test results to the extent necessary to record and track participants' credits. Contact UsIf you have any questions or comments, please email us at contactus@paradigmmc.com. © 2019 Paradigm Medical Communications, LLC, except where noted. Content may not be reproduced in whole or part without the express written permission of Paradigm Medical Communications, LLC.",https://t.co/lYbzP4rEUr,others
GLP1 Receptor Agonists,"What are GLP-1 receptor agonist medicines?GLP-1 receptor agonist medicines, also called incretin mimetics, are a type of incretin-based medicine for type 2 diabetes. This type of medicine is based on the action of hormones called incretins, which help control how the pancreas works. One type of incretin, called GLP-1, causes your pancreas to produce more insulin after you eat and helps keep blood glucose levels in the normal range. These medicines (exanatide, dulaglutide, lixisenatide and liraglutide) copy, or mimic, the action of GLP-1 made by your body. The effects of GLP-1 only last for a few minutes, but GLP-1 receptor agonists medicines can last for hours or days.GLP-1 receptor agonists come as a liquid, which you inject under the skin on your abdomen, thigh, or upper arm. Depending on which medicine you use, you inject it either once or twice daily, or once weekly. GLP-1 receptor agonists are used alone or along with other diabetes medicines.What are the benefits of GLP-1 receptor agonist medicines?They help keep your blood glucose from going too high by:Increasing the insulin made by your pancreasDecreasing glucagon, a hormone that releases glucose from your liverHelping you feel full after a meal, which means that you eat lessSlowing the emptying of the stomach's contents into the intestines, which lowers blood glucose levels after a mealWhat are the side effects and disadvantages of GLP-1 receptor agonist medicines?GLP-1 receptor agonists don't cause low blood glucose, a condition called hypoglycemia. But you're at risk for low blood glucose if you also take diabetes pills or insulin that may cause hypoglycemia. Low blood glucose can make you feel hungry, dizzy, nervous, shaky, or confused. You can learn what to eat or drink to bring your blood glucose level back up to normal.GLP-1 receptor agonists can cause nausea, vomiting, diarrhea, headache, weakness, or dizziness. Some side effects are warning signs of serious conditions. For example, nausea and vomiting with abdominal pain could be pancreatitis (inflammation of the pancreas). Ask your doctor which signs to watch for and what to do if those signs happen.How will I know which diabetes medicines are best for me?Talk with your doctor about your diabetes medicines. Ask if there are other medicines that can help you, or if you should use more than one medicine. Tell your doctor about any side effects you have from your medicines. Be sure to tell your doctor about your other health conditions and whether you are pregnant or planning to become pregnant. Then your doctor can make the best choice of medicine for you.",https://t.co/SkCRTWQCtd,others
My Hi Fiber Diet,"Select and find out more about high-fiber foods from the food bank, add your own branded and other foods, create your own high-fiber recipes, and monitor your daily fiber intake to achieve your recommended daily amount (RDA) with this super easy-to-use enticing new app. Well-documented health benefits of a high-fiber diet include a lower risk of high cholesterol, hypertension, heart attack, stroke, type 2 diabetes, many types of cancer, dementia, depression, anxiety and stress — likely due to the effect of fiber on gut bacteria; slowed chromosomal and biologic aging; and a lower risk of being overweight. A high-fiber diet also protects from a variety of abdominal symptoms, constipation and piles. Use the ""Settings"" tab to select your preferred metrics (g or oz) and sex (fiber RDA differs for men and women), while the ""Home"" tab provides quick access to your favorite foods and recipes, nutritional information, weight guides for commonly used portions of food, and descending order lists of fiber content for over 300 common foods (the food bank) in g and %RDA. Short touch any food name for a pop-up with the fiber content in g and %RDA and an option to favorite/unfavorite the food; long touch any of the 250 ""healthy"" foods (in black type) for nutritional information including heart healthy scores, and in many cases preparation tips and a photo. Use the ""Add foods and recipes"" tab to input ""branded"" and other foods and recipes not provided in the food bank, and the ""Monitor fiber intake"" tab to record your fiber intake in g or oz and %RDA, which can then be viewed as a bar chart. Touch any bar in the bar chart for any chosen day for a pop-up detailing the food intake contributing to the bar. Use the ""Find"" tab for rapid access to the fiber content of foods in the food bank, your favorite foods, and foods and recipes you add to the app. Really useful hyperlinks are provided throughout to nutritional and healthy food information.No internet, personal details, or additional payments are required. The interface is easy, quick, and intuitive to navigate, zoomable using the pinch screen function, and viewable in landscape and portrait.",https://t.co/41kPPheQ9W,others
"Glucagon reduces airway hyperreactivity, inflammation, and remodeling induced by ovalbumin","ChemicalsDexamethasone, glucagon, indomethacin, methacholine, nembutal, and OVA (Grade V) were purchased from Sigma Chemical Co (St. Louis, USA). Pancuronium bromide and sodium thiopental were purchased from Cristália (São Paulo, Brazil). Dexamethasone, glucagon, OVA, pancuronium bromide, nembutal, and sodium thiopental were dissolved in 0.9% NaCl sterile solution. Methacholine was diluted in phosphate-buffered saline (PBS). Indomethacin was prepared in DMSO 0.3%. All of the solutions were freshly prepared immediately before use.AnimalsSix to eight-week-old (18–20 g) male A/J mice and DO11.10 TCR Tg mice were obtained from the Oswaldo Cruz Foundation breeding colony and used in accordance with the guidelines of the Committee on Use of Laboratory Animals of the Oswaldo Cruz Institute (CEUA-IOC/FIOCRUZ), and all the experimental protocols used in this work were approved by CEUA-IOC/FIOCRUZ (license L-027/2016). Mice were housed in groups of five in a temperature, humidity, and light controlled (12 h light/dark period) colony room. Mice were given ad libitum access to food and water.Sensitization, antigen challenge, and treatment protocolA/J mice were sensitized with a subcutaneous injection of sterile saline solution (0.2 mL) containing OVA (50 µg) and the adjuvant aluminum hydroxide Al(OH)3 (5 mg). After 14 days, all mice were boosted following the same procedure. On the 19th day after sensitization, the animals were subjected to an i.n. challenge of OVA (25 μg/25 μL) or sterile saline (0.9%) for 2 consecutive days, once daily. Analyses were performed 24 h after the last challenge using OVA, which corresponded to the 21st day after sensitization. Treatment with glucagon (0.1–100 µg/Kg, i.n.) or its vehicle (sterile saline 0.9%, i.n.) were performed once a day 1 h before each OVA challenge. In some experiments, the animals were pretreated intraperitoneally with indomethacin (10 mg/Kg, i.p.)14 or its vehicle (DMSO 0.3%) 30 min before glucagon injection (100 µg/Kg, i.n.).Bronchoalveolar LavageTwenty-four hours after the last challenge using sterile saline or OVA, A/J mice were euthanized by injection of sodium thiopental (500 mg/Kg, i.p.). Then, the airways were lavaged with two injections of 0.75 mL of PBS containing 10 mM methylenediaminetetraacetic acid (EDTA). BAL fluid was centrifuged (300 × g, 10 min, 4 °C) and cell pellets were resuspended in 250 μL of PBS plus EDTA (10 mM). To quantify the leukocyte influx into the airway lumen, BAL effluent was diluted in Türk solution (2% acetic acid) and total leukocytes were counted in a Neubauer chamber, using a light microscope (BX40; Olympus, Center Valley, PA). Differential cell counts were performed in cytospin smears stained with the May-Grünwald Giemsa method and analyzed using a light microscope (BX40, Olympus).Analysis of mediastinal lymph node cellsAfter the last challenge using sterile saline or OVA, the mediastinal lymph node was extracted, mechanically macerated and cell aggregates were removed using a plastic strainer (Cell strainer 40 μm, BD Biosciences Pharmingen, San Jose, CA, USA) in a petri dish with Dulbecco's modified Eagle's medium (DMEM; Sigma-Aldrich) supplemented with penicillin 1 × 106 U/Ml (Sigma-Aldrich); 0.2 g/mL streptomycin (Sigma-Aldrich); 10% fetal bovine serum (FBS). The macerate was centrifuged (433 x g for 10 min at 4 °C), and then, the pellet was resuspended in 1 mL of the supplemented DMEM. All samples were diluted in the Turk dye solution (2% acetic acid) for the quantification of total cells in a Neubauer chamber using a light microscope (BX40; Olympus).ImmunohistochemistryParaffin-embedded sections (5 µM) of the left lung were boiled in 10 mM sodium citrate (pH 6.0) for 15 min for antigen retrieval. To block endogenous peroxidase activity, the tissue sections were incubated with hydrogen peroxide (3%) in methanol for 20 min. Non-specific binding sites were blocked using FBS (8%), bovine serum albumin (BSA, 2.5%), and non-fat milk (1%) diluted in Tris-buffered saline (TBS) enriched with 0.1% Tween 20 (TBST) for 3 h. All sections were incubated overnight at 4 °C with primary polyclonal rabbit anti-GcgR (1:100; Santa Cruz Biotechnology, Santa Cruz, USA) antibody diluted in TBST plus 1% BSA. Then, we incubated the sections with horseradish peroxidase-conjugated streptavidin (HRP) (polyclonal anti-rabbit IgG (1:100), R&amp;D System, MN, USA) for 2 h 30 min at room temperature followed by a 20-min exposure to the enzyme substrate 3-amino-9-ethylcarbazole (AEC). The sections were counterstained using hematoxylin for 10 s to visualize the structure of the lungs. In negative control experiments, the primary antibody was omitted. The slides were scanned using a 3DHISTECH–Pannoramic MIDI whole slide scanner (Budapest, Hungary) and captured with a 20× objective lens. The analyses were performed using Image-Pro-Plus® software version 6.2 (Media Cybernetics Inc, Bethesda, MA, USA), and the number of positive pixels was divided by the field area and expressed as pixels/μm2.Invasive assessment of airway hyperreactivity to methacholineAHR was determined as an increase reactivity of the airways to aerosolization of methacholine 24 h after the last sterile saline or OVA challenge. Mice were anesthetized using nembutal (60 mg/Kg, i.p.), and neuromuscular activity was blocked by pancuronium bromide (1 mg/Kg, i.p.). Pulmonary function and AHR were assessed in tracheostomized and mechanically ventilated mice using a FinePointe R/C Buxco Platform (Buxco® Electronics, Sharon, CT, USA), as previously described14.Eosinophil peroxidase activity in lung tissueThe EPO activity assay is a well-established and accurate method for measuring the number of eosinophils in biological samples, as described previously16,17. This method allows quantification of the reaction of peroxidases secreted by eosinophils through an optical absorbance measurement18. Briefly, one lobe of the right lung was homogenized in 5% Hank's Balanced Salt Solution (HBSS) and centrifuged at 960 × g for 10 min at 4 °C. After red blood cells lysis, we added 5% HBSS containing 0.5% hexadecyltrimethyl ammonium bromide to samples and performed three successive cycles of freezing and thawing. After centrifugation (1090 × g for 10 min at 4 °C), the samples were placed (75 μL/well) in a 96-well plate, and then, we added 150 μL of substrate (1.5 mM o-phenylenediamine and 6.6 mM hydrogen peroxide in 0.05 M Tris-HCl, pH 8.0) and incubated for 30 min at room temperature. Then, the reaction was stopped by the addition of 75 μL of 4 M sulfuric acid and the absorbance was read at 492 nm (Spectra Max M5, Molecular Devices, Sunny vale, CA, USA). The results are represented as optical density (OD) per ρg of protein in each sample. Protein was quantified by the Bicinchoninic acid (BCA) assay (Sigma-Aldrich Corp).Evaluation of GcgR expression on T cells, TCD4+ cells, TCD8+ cells, eosinophils, neutrophils, and dendritic cellsCells obtained from BAL or mediastinal lymph nodes of mice challenged with OVA or sterile saline in vivo were analyzed by flow cytometry (FACSAria II; BD Biosciences PharMingen or FACSCalibur; BD Biosciences PharMingen). We labeled the cells using monoclonal antibodies anti-CD3 (FITC or PECF-594), anti-CD4 (APC or FITC), anti-CD8 (PECy5), anti-SiglecF (PE) (BD Biosciences PharMingen), anti-Ly6G (FITC), anti-CD11c (PE) (Thermo Fisher Scientific, Swedesboro, NJ, USA) or polyclonal antibody anti-GcgR (PE) (Bioss Antibodies, Woburn, MA, USA). To evaluated GcgR expression on Total CD3+ cells, TCD4+ cells, eosinophils, neutrophils, and dendritic cells in BAL, we incubated these cells with primary polyclonal rabbit anti-GcgR (Santa Cruz Biotechnology) antibody for 30 min, washed with PBS, and then we incubated the cells with polyclonal anti-rabbit-Alexa 635 antibody (BD Biosciences PharMingen) for 30 min. In control nonspecific binding, we used an isotype-matched antibodies or the primary polyclonal rabbit antibody anti-GcgR (Santa Cruz Biotechnology) was omitted. The results were analyzed using Summit software version 4.3 (Beckman Coulter.). Gating strategies for identification of populations are shown in Figs S2, S3, S7 and S8.Western blotOne lobe of the right lung was homogenized in cold lysis buffer containing a cocktail for protease and phosphatase inhibitors (1:100; Thermo Fisher Scientific). The homogenates were centrifuged (13,000 × g for 10 min at 4 °C), the supernatant was collected, and the total proteins were quantified by using BCA method (Sigma–Aldrich Corp). Total proteins (50 µg/lane) were resolved using 10% SDS-PAGE and then transferred to nitrocellulose membranes. The membranes were blocked using nonfat dry milk (5%) in TBS for 1 h at room temperature and incubated overnight at 4 °C with biotin conjugated anti-TCR α/β (1:100; MyBioSource, San Diego, USA). Next, the membranes were rinsed in blocking buffer and incubated with HRP-secondary antibody (Dako, Carpinteria, CA) for 1 h at room temperature. For loading control, nitrocellulose membranes were incubated with anti-β-actin (1:5000; Sigma-Aldrich Corp.) overnight at 4 °C, rinsed in blocking buffer, and incubated with HRP goat anti-mouse (1:10,000; R&amp;D Systems) for 1 h at room temperature. Detections were performed using 3,3′-diaminobenzidine (DAB)-peroxidase substrate solution (Vector Labs, Burlingame, CA). The membranes were scanned, and band intensity was quantified by densitometry using the software Image Studio Lite version 4.0 (LI-COR Corporate, Lincoln, NE, USA).Quantification of cytokines and chemokines in lungsOne lobe of the right lung was homogenized in cold lysis buffer containing the protease inhibitor cocktail Complete (F. Hoffmann-La Roche Ltd., Basel, Switzerland) and 0.1% Triton X-100 in PBS 1X. After centrifugation (13,000 × g for 10 min at 4 °C) of the lysate, the supernatant levels of murine Eot-1/CCL11, Eot-2/CCL24, MDC/CCL22, and TARC/CCL17, IL-4, IL-5, IL-13, and TNF-α were measured using a commercially available enzyme linked immunosorbent assay (ELISA) kits (R&amp;D Systems) according to the manufacturer's instructions. The results were expressed as ρg of cytokine or chemokine per lung.Measurement of Pulmonary Inflammation and Peribronchiolar FibrosisThe left lung was fixed in Milloning buffer solution (pH 7.4) with 4% paraformaldehyde to preserve the pulmonary architecture. Lung sections were stained using Sirius Red (pH 10.2) or Masson's trichrome for the analysis of peribronchiolar leukocyte infiltration and extracellular matrix deposits, respectively, as described previously19,20. The slides stained using Masson's trichrome were scanned with 3DHISTECH–Pannoramic MIDI whole slide scanner, and the images were captured using a 20× objective lens. The analysis was performed in 10 bronchioles per animal in a double-blind experiment evaluating the use of Image-Pro-Plus® software version 6.2 (Media Cybernetics Inc,). The quantification of eosinophils, neutrophils and mononuclear cells number on the peribronchiolar region was performed under an optical microscope (BX40; Olympus) through an integrating eyepiece. The morphometric reticulum had a known area of 104 μm2 at the final magnification of 1,000× and was randomly positioned over the peribronchiolar regions. Three different fields were analyzed for bronchioles in 7 bronchioles per animal19,20.Quantification of lung collagenThe right lung was homogenized in Tris-HCl 0.05 M and NaCl 1 M solution containing Complete (Hoffmann-La Roche) (pH 7.4). Total soluble collagen was extracted overnight at room temperature and its levels were measured using Sircol kit (Biocolor, Newton Abbey, U.K.) according to the manufacturer's instructions. The results were expressed as milligrams collagen per right lung27.Analysis of T cell proliferation and cytokine production in vitro Pooled T lymphocytes from cervical, axial and inguinal lymph nodes (1 × 106/well) were obtained from A/J mice or naïve DO11.10 TCR Tg mice and stimulated with immobilized anti-CD3 (1 µg/mL; BD Biosciences Pharmingen) or soluble OVA (0.5 mg/mL), respectively. Cells were incubated with dexamethasone (1 μM) or glucagon (0.03–3 μM) for 72 h at 37 °C in 5% CO2. For the analysis of cell viability, aliquots of cell suspensions were mixed with trypan blue solution (0.2%) and all cells presented at least 85% of viability in all groups studied. Proliferation was analyzed by permeabilizing and staining the cells with propidium iodide (PI) as previously described21. Proliferation values were determined by calculating the percentage of cells in phase S + G2 of the cell cycle. In the protocol of T cells stimulated with anti-CD3 in vitro, cytokines IL-2, IL-10 and IL-17 were detected from the supernatant of these cells using a Cytometric Bead Array (CBA) kit (BD Biosciences PharMingen), while in OVA-induced T cells activation in vitro, the cytokine IL-13 was evaluated by ELISA kits (R&amp;D Systems), according to the manufacturer's instructions.Isolation of mice naïve TCD4+ cellsPooled cells from cervical, axial and inguinal lymph nodes were obtained from A/J naïve mice and TCD4+ cells were isolated by magnetic bead depletion of TCD8+ cells, B cells, monocytes/macrophages, NK cells, dendritic cells, erythrocytes, and granulocytes (Dynal Mouse CD4 negative Isolation Kit, Invitrogen, Carlsbad, CA, USA). After isolation, the purity of TCD4+ cells, attested by flow cytometry (FACSCalibur; BD Biosciences PharMingen), was higher than 93%. Gating strategies for identification of CD3+CD4+ population in lymph nodes before or after negative isolation are shown in Fig. S9.Analysis of TCD4+ cell proliferation and cytokine production in vitro Isolated TCD4+ cells (2 × 104/well) were obtained from A/J mice and stimulated with immobilized anti-CD3 plus anti-CD-28 (0.5 µg/ml and 1 µg/mL, respectively; BD Biosciences Pharmingen). Cells were incubated with dexamethasone (1 μM) or glucagon (3 μM) for 72 h at 37 °C in 5% CO2. Proliferation was measured by BrdU incorporation using the Cell Proliferation ELISA, BrdU colorimetric kit (Millipore, Burlington, MA, USA) according to the manufacturer's instructions. To evaluate the production of cytokines IL-2, IL-4, IL-10, and TNF-α, isolated TCD4+ cells (5 × 105 cells/well) were stimulated with immobilized anti-CD3 plus anti-CD-28 (1 and 2 µg/mL, respectively) and were detected from the supernatant of these cells using a CBA kit (BD Biosciences PharMingen).Intracellular cAMP quantificationFor cAMP quantification, 5 × 104 TCD4+ cells were treated with 500 nM of IBMX (a competitive nonselective phosphodiesterase inhibitor) and, after 15 min, with glucagon (3 µM) or forskolin (100 µM), for 20 min. Culture supernatants were removed, cells were lysed with 0.1 M HCl, and intracellular cAMP levels were determined by ELISA according to the manufacturer's instructions (Cayman Chemical, Ann Arbor, MI, USA).Statistical AnalysisThe data were reported as the mean ± standard error of the mean (SEM) and then evaluated to ensure a normal distribution. All data were statistically analyzed using a one-way ANOVA followed by Newman–Keuls–Student's t-test except for the study of AHR, which was examined using two-way ANOVA followed by Bonferroni post-test, and the quantification of intracellular cAMP, which was analyzed by unpaired t-test, with GraphPad Prism 5.0 (Graphpad Software, San Diego, CA, USA). Probability values (P) of 0.05 or less were considered significant.",https://t.co/6MiJnXmISJ,others
Minerva,"In het titratieschema van de glykemieverlagende behandeling voor type 2-diabetes mellitus nemen glucagon-like peptide-1 (GLP-1)-analogen, ook wel incretinemimetica genoemd, dezelfde plaats in als basaal insuline (1). Ze worden toegevoegd aan orale antidiabetica wanneer deze niet meer volstaan om de glykemiestreefwaarde te bereiken (1). In vergelijking met placebo is aangetoond dat ze geen aanleiding geven tot hypoglykemische episodes en dat ze gepaard gaan met gewichtsverlies (2,3). Een directe vergelijking tussen GLP-1-analogen en basaal insuline kan dus nuttig zijn voor de klinische besluitvorming. Een systematische review met meta-analyse includeerde 11 head-to-head-studies die het effect van een subcutane toediening van GLP-1-analogen in vergelijking met basaal insuline als aanvullende behandeling bij orale antidiabetica op HbA1c en lichaamsgewicht onderzochten (4). Alle GLP-1-analogen resulteerden versus insuline glargine in een gewichtsdaling van -1,98 kg (95% BI van -2,32 tot -1,64) met wekelijks 75 mg dulaglutide tot -4.31 kg (95% BI van -4,71 tot -3,90) met exenatide 10 µg tweemaal per dag. Het effect op HbA1c was minder eenduidig. Alleen met een wekelijkse toediening van 2 mg exenatide versus insuline glargine en versus insuline detemir en met een wekelijkse toediening van 0,75 mg en 1,5 mg dulaglutide versus insuline glargine zag men een statistisch significante daling van HbA1c van respectievelijk -0,31% (95% BI van -0,42 tot -0,19), -0,42% (95% BI van -0,54 tot -0,20), -0,39% (95% BI van -0,49 tot -0,29) en -0,58% (95% BI van -0,72 tot -0,44). Er was geen statistisch significant verschil in HbA1c met een subcutane toediening van 1,8 mg liraglutide eenmaal per dag en van 10 µg exenatide tweemaal per dag in vergelijking met insuline glargine. Een andere systematische review en meta-analyse die GLP-1-analogen zowel vergeleek met basaal insuline als met een basaal-bolus-schema kwam tot vergelijkbare bevindingen (5). Men zag geen daling van HbA1c met kortwerkende GLP-1-analogen maar wel met langwerkende GLP-1-analogen versus basaal insuline (-0,17% met 95% BI van -0,22% tot -0,12%). In vergelijking met een basaal-bolus-schema kon met GLP-1-analogen geen statistisch significant verschil in HbA1c aangetoond worden. Echter bleek ook dat basaal insuline in vergelijking met GLP-1-analogen een sterker effect had op nuchtere glykemie (-1,78 mmol/L met 95% BI van -1,83 tot -1,73). Anderzijds zag men andere voordelen met GLP-1-analogen versus basaal insuline: gewichtsdaling (-3,71 kg met 95% BI van -3,88 tot -3,54), absolute risicoreductie van 15,6% (met 95% BI van 13,1 tot 18,1%) in hypoglykemische episodes (P &lt;0,0001), absolute daling van 2,8 mmHg (95% BI van -3,6 tot -2,0) in systolische bloeddruk en van 0,23 mmol/l (met 95% BI van -0,31 tot -0,16) in triglyceridenconcentratie en van 0,13 mmol/l (met 95% BI van -0,18 tot -0,09) in LDL-cholesterolconcentratie, zonder verschil in HDL-cholesterolconcentratie. Of deze winst in intermediaire uitkomstmaten ook zal leiden tot minder cardiovasculaire gebeurtenissen is nog onduidelijk. Besluit Uit twee systematische reviews met meta-analyse blijkt dat GLP-1-analogen een veilig alternatief zijn voor basaal insuline in het titratieschema van glykemieverlagende behandeling voor patiënten met type 2-diabetes mellitus. Langwerkende preparaten zijn hierbij effectiever gebleken dan kortwerkende preparaten. Voor de praktijkWanneer een combinatie van orale antidiabetica aan maximaal getolereerde dosis onvoldoende is om de individuele HbA1c-streefwaarde te bereiken, wordt aanbevolen om insuline of een GLP-1-analoog aan de behandeling toe te voegen (GRADE 1B) (1). Bij het opstarten van insulinetherapie is een basaal insuline (NPH) voor het slapengaan te verkiezen (GRADE 1A). Bij het optreden van hypoglykemische episodes is een overschakeling naar langwerkende insuline-analogen (insuline glargine) te overwegen (GRADE 1C). Een GLP-1-analoog is te verkiezen voor patiënten met obesitas of patiënten bij wie hypoglykemie een bijzonder gevaar vormt (GRADE 1C). Het is belangrijk om specifieke educatie en zelfcontrole te voorzien bij het opstarten van een GLP-1-agonist of insuline (GRADE 1A). Twee systematische reviews met meta-analyse bevestigen dat de effectiviteit van basaal insuline en GLP-1-analogen vergelijkbaar is. Met GLP-1-analogen werd ten opzichte van basaal insuline gewichtsdaling vastgesteld. Referenties Insulinetherapie bij type 2 diabetes. Duodecim Medical Publications. Laatste update: 6/08/2017. Laatste contextnazicht: 11/04/2019. Ruige J. Exenatide toevoegen aan een oraal antidiabeticum bij ongecontroleerde type 2-diabetes? Minerva 2008;7(2):22-3. Zinman B, Hoogwerf BJ, Duran Garcia SD, et al. The effect of adding exenatide to a thiazolidinedione in suboptimally controlled type 2 diabetes. Ann Intern Med 2007;146:477-85. DOI: 10.7326/0003-4819-146-7-200704030-00003 Singh S, Wright EE, Kwan AY, et al. Glucagon-like peptide-1 receptor agonists compared with basal insulins for the treatment of type 2 diabetes mellitus: a systematic review and meta-analysis. Diabetes Obes Metab 2017;19:228-38. DOI: 10.1111/dom.12805 Abd El Aziz MS, Kahle M, Meier JJ, Nauck MA. A meta-analysis comparing clinical effects of short- or long-acting GLP-1 receptor agonists versus insulin treatment from head-to-head studies in type 2 diabetic patients. Diabetes Obes Metab 2017;19:216-27. DOI: 10.1111/dom.12804",https://t.co/BtVvkJAtGf,others
